Clinical trial NCT04011241
Conditions: Healthy
Sponsor: Boehringer Ingelheim
Start date: 2019-07-24; Completion date: 2019-09-06
Enrollment: 14 participants; Allocation: NON_RANDOMIZED; Intervention model: CROSSOVER

Brief summary:
The main objective of this trial is to investigate the relative bioavailability of BI 1323495 in plasma when given as oral single dose together with multiple oral doses of itraconazole (Test,T) as compared to when given alone as oral single dose (Reference, R).

Detailed description:

Arms: arm 1: Single oral dose of 10 milligrams (mg) of film-coated tablet of BI 1323495 was administered once on day 1 in the first treatment period (period 1, visit 2) with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h) as reference treatment R. arm 2: Single oral dose of 200 mg itraconazole (oral solution, 20 milliliter (mL) per day with 10 mg/mL) was administered once daily with 240 mL of water after an overnight fast of 9 hours (h) from day -3 to day 7 (total: 10 doses) in the second treatment period (period 2, visit 3) together with a single oral dose of 10 mg BI 1323495 administered 1 h after itraconazole administration with 240 mL of water after an overnight fast of 10 h on the fourth day of the itraconazole treatment (day 1, period 2, visit 3) as test treatment T.
Interventions: intervention 1: BI 1323495 intervention 2: Itraconazole
Intervention descriptions: intervention 1: Tablet intervention 2: Oral solution

Protocol documents:
Prot_000.pdf: 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Clinical Trial Protocol
TITLE PAGE
Document Number:
c26556329-02
EudraCT No.
2019-001570-28
BI Trial No.
1405-0009
BI Investigational
Medicinal Product
BI 1323495
Title
Relative bioavailability of a single oral dose of BI 1323495 when 
administered alone or in combination with multiple oral doses of 
itraconazole in healthy male subjects (an open-label, one-way 
crossover study)
Lay Title
A study in healthy men to test how itraconazole influences the 
amount of BI 1323495 in the blood
Clinical Phase
I
Clinical Trial Leader
Phone: 
Fax: 
Principal 
Investigator
Phone: 
Fax: 
Status
Final Protocol (Revised Protocol (based on global amendment 1))
Version and Date
Version: 2.0
Date: 18 June 2019
Page 1 of 62
Proprietary confidential information
© 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved.
This document may not - in full or in part - be passed on, reproduced, published or otherwise used without prior written permission


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 2 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
CLINICAL TRIAL PROTOCOL SYNOPSIS
Company name
Boehringer Ingelheim
Protocol date
18 June 2019
Revision date
Not applicable
BI trial number
1405-0009
Title of trial
Relative bioavailability of a single oral dose of BI 1323495 when administered 
alone or in combination with multiple oral doses of itraconazole in healthy male 
subjects (an open-label, one-way crossover study)
Principal Investigator
Trial site
Clinical phase
I
Trial rationale
Based on in vitro data, CYP3A4 and P-gp are involved in metabolism and transport 
of BI 1323495, respectively. It is therefore necessary to explore the relative 
bioavailability of BI 1323495 in plasma when given alone versus when given 
together with a strong CYP3A4 and P-gp inhibitor.
Trial objective
To investigate the relative bioavailability of a single oral dose of BI 1323495 when 
given alone (treatment R) or in combination with itraconazole (treatment T).
Trial design
Open-label, two-treatment, two-period, one-way crossover design
Trial endpoints
Primary endpoints: AUC0-tz and Cmax of BI 1323495
Secondary endpoints: AUC0-of BI 1323495
Number of subjects 
total entered
14
each treatment
14
Diagnosis
Not applicable
Main criteria
for inclusion
Healthy male subjects, age of 18 to 50 years (inclusive), body mass index (BMI) of 
18.5 to 29.9 kg/m2 (inclusive), 
Test product 1
BI 1323495 tablet formulation
dose
mode of admin.
Oral with 240 mL of water after an overnight fast of at least 10 h 


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 3 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Test product 2
Itraconazole oral solution (Sempera® Liquid 10 mg/mL)
dose
200 mg q.d.
mode of admin.
Oral with 240 mL of water after an overnight fast of at least 9 h 
Duration of treatment
Treatment R (BI 1323495 alone):
Single dose of 
 BI 1323495 (Day 1)
Treatment T (itraconazole + BI 1323495):
10 days of itraconazole treatment (200 mg itraconazole once daily from Day -3 to 
Day 7) combined with a single dose of 
 BI 1323495 on the fourth day of the 
itraconazole treatment (Day 1, 1 h after the itraconazole administration)
Wash-out period:
Administrations of BI 1323495 will be separated by a wash-out phase of at least 7
days
Statistical methods
Relative bioavailability will be estimated by the ratios of the geometric means 
(test/reference) for the primary and secondary endpoints. Additionally, their two-
sided 90% confidence intervals (CIs) will be provided. This method corresponds to 
the two one-sided t-test procedure, each at a 5% significance level. Since the main 
focus is on estimation and not testing, a formal hypothesis test and associated 
acceptance range are not specified. The statistical model will be an analysis of 
variance (ANOVA) on the logarithmic scale including effects for ‘subject’ and 
‘treatment’. CIs will be calculated based on the residual error from the ANOVA.
Descriptive statistics will be calculated for all endpoints.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 4 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
FLOW CHART
Period
Visit
Day
Planned time (relative to 
drug administration)
[h:min]
Approximate clock time  
of actual day [h:min]
Event and comment
Safety laboratory5
PK blood, BI 1323495
PK blood, Itraconazole
12-lead ECG
Vital signs (BP, PR)
Questioning for AEs and 
concomitant therapy 7
SCR
1
-21 to -3
Screening (SCR)1
xA
x
x
Period 1/ Treatment R (BI 1323495 alone)8
2
-3 to -1
-75:00
06:00
Ambulatory visit
xB
x
1
-3:00
06:00
Admission to trial site2
x2,3
x2
x2
x2
x2
x2
0:00
09:00
BI 1323495 administration
0:20
09:20
x
0:40
09:40
x
1:00
10:00
x
2:00
11:00
240 mL fluid intake
x
3:00
12:00
x
4:00
13:00
240 mL fluid intake, thereafter lunch4
x
x
x
x
5:00
14:00
x
6:00
15:00
x
7:00
16:00
Snack (voluntary)4
x
8:00
17:00
x
10:00
19:00
Dinner4
x
12:00
21:00
x
x 
2
24:00
09:00
Breakfast (voluntary)4,
discharge from trial site
xB
x
x
x
x
34:00
19:00
Ambulatory visit
x
x
3
47:00
08:00
Ambulatory visit
x
x
4
71:00
08:00
Ambulatory visit
xB
x
x
5
95:00
08:00
Ambulatory visit
x
x
1.
Subject must be informed and written informed consent obtained prior to starting any screening procedures. Screening 
procedures include physical examination, check of vital signs, ECG, safety laboratory (including drug screening), 
 demographics (including determination of body height and weight, 
smoking status and alcohol history), relevant medical history, concomitant therapy and review of inclusion/exclusion 
criteria. 
2.
The time is approximate; the procedure is to be performed and completed within the 3 h prior to drug administration.
3.
Urine drug screening and alcohol breath test
4.
If several actions are indicated at the same time, the intake of meals will be the last action.
5.
Letters A, B, C, and D define different sets of safety laboratory examinations (for details refer to Section 5.2.3)
6.
At the end of trial visit the EoTrial examination includes physical examination, vital signs, ECG, safety laboratory, 
recording of AEs and concomitant therapies. 
7.
AEs and concomitant therapies will be recorded throughout the trial, but will be specifically asked for at the times 
indicated in the Flow Chart above.
8.
Administration of BI 1323495 in treatment R and T will be separated by at least 7 days.
9.
Blood collection takes place at the indicated times. Itraconazole will be administered immediately thereafter.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 5 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
FLOW CHART (cont’d)
Period
Visit
Day
Planned time (relative to 
drug administration)
[h:min]
Approximate clock time  
of actual day [h:min]
Event and comment
Safety laboratory5
PK blood, BI 1323495
PK blood, Itraconazole
12-lead ECG
Vital signs (BP, PR)
Questioning for AEs and 
concomitant therapy 7
Period 2/ Treatment T (BI 1323495 + itraconazole) 8
3
-3
-73:00
08:00
Ambulatory visit, itraconazole administration
xB,2,3
x2
-2
-49:00
08:00
Ambulatory visit, itraconazole administration
x2
-1
-25:00
08:00
Ambulatory visit, itraconazole administration
xC,2
x9
x2
1
-3:00
06:00
Admission to trial site2
x2
x2
x2
x2
-1:00
08:00
Itraconazole administration
x9
0:00
09:00
BI 1323495 administration
0:20
09:20
x
0:40
09:40
x
1:00
10:00
x
2:00
11:00
240 mL fluid intake
x
3:00
12:00
x
4:00
13:00
240 mL fluid intake, thereafter lunch4
x
x
x
x
5:00
14:00
x
6:00
15:00
x
7:00
16:00
Snack (voluntary)4
x
8:00
17:00
x
10:00
19:00
Dinner4
x
12:00
21:00
x
x 
2
23:00
08:00
Itraconazole administration
xB,2
x
24:00
09:00
Breakfast (voluntary)4
x
x
x
x
28:00
13:00
Lunch (voluntary)
31:00
16:00
Snack (voluntary)
34:00
19:00
Discharge from trial site
x
x
3
47:00
08:00
Ambulatory visit, itraconazole administration
x9
x9
x
4
71:00
08:00
Ambulatory visit, itraconazole administration
xC,2
x9
x
5
95:00
08:00
Ambulatory visit, itraconazole administration
x9
x
6
119:00
08:00
Ambulatory visit, itraconazole administration
xC,2
x9
x
7
143:00
08:00
Ambulatory visit, itraconazole administration
x9
x9
x
8
167:00
08:00
Ambulatory visit
xB
x
x
x
FU
4
16 to 23
End of trial (EoTrial) examination6
xD
x
x
x
1.
Subject must be informed and written informed consent obtained prior to starting any screening procedures. Screening 
procedures include physical examination, check of vital signs, ECG, safety laboratory (including drug screening), 
 demographics (including determination of body height and weight, 
smoking status and alcohol history), relevant medical history, concomitant therapy and review of inclusion/exclusion 
criteria. 
2.
The time is approximate; the procedure is to be performed and completed within the 3 h prior to drug administration.
3.
Urine drug screening and alcohol breath test
4.
If several actions are indicated at the same time, the intake of meals will be the last action.
5.
Letters A, B, C, and D define different sets of safety laboratory examinations (for details refer to Section 5.2.3)
6.
At the end of trial visit the EoTrial examination includes physical examination, vital signs, ECG, safety laboratory, 
recording of AEs and concomitant therapies. 
7.
AEs and concomitant therapies will be recorded throughout the trial, but will be specifically asked for at the times 
indicated in the Flow Chart above.
8.
Administration of BI 1323495 in treatment R and T will be separated by at least 7 days.
9.
Blood collection takes place at the indicated times. Itraconazole will be administered immediately thereafter.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 6 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
TABLE OF CONTENTS
TITLE PAGE ......................................................................................................1
CLINICAL TRIAL PROTOCOL SYNOPSIS ................................................2
FLOW CHART...................................................................................................4
TABLE OF CONTENTS ...................................................................................6
ABBREVIATIONS.......................................................................................... 10
1.
INTRODUCTION.................................................................................... 13
1.1
MEDICAL BACKGROUND............................................................................13
1.2
DRUG PROFILE...............................................................................................13
1.2.1
BI 1323495 .............................................................................................13
1.2.2
Itraconazole ...........................................................................................15
1.2.3
Residual Effect Period..........................................................................15
1.3
RATIONALE FOR PERFORMING THE TRIAL........................................16
1.4
BENEFIT - RISK ASSESSMENT ...................................................................16
1.4.1
Procedure-related risks ........................................................................16
1.4.2
Drug-related risks and safety measures..............................................16
1.4.2.1
Drug-induced liver injury ........................................................16
1.4.2.2
BI 1323495...............................................................................17
1.4.2.3
Itraconazole..............................................................................18
1.4.2.4
Potential interaction between itraconazole and BI 1323495....19
1.4.2.5
Safety Measures.......................................................................19
1.4.2.6
Benefit –Risk Assessment Summary.......................................19
2.
TRIAL OBJECTIVES AND ENDPOINTS........................................... 20
2.1
MAIN OBJECTIVES, PRIMARY AND SECONDARY ENDPOINTS ......20
2.1.1
Main objectives......................................................................................20
2.1.2
Primary endpoints ................................................................................20
2.1.3
Secondary endpoint ..............................................................................20
3.
DESCRIPTION OF DESIGN AND TRIAL POPULATION.............. 22
3.1
OVERALL TRIAL DESIGN AND PLAN ......................................................22
3.2
DISCUSSION OF TRIAL DESIGN, INCLUDING THE CHOICE OF 
CONTROL GROUPS........................................................................................22
3.3
SELECTION OF TRIAL POPULATION ......................................................23
3.3.1
Main diagnosis for trial entry..............................................................23


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 7 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
3.3.2
Inclusion criteria...................................................................................23
3.3.3
Exclusion criteria ..................................................................................23
3.3.4
Withdrawal of subjects from treatment or assessments ...................25
3.3.4.1
Discontinuation of trial treatment............................................25
3.3.4.2
Withdrawal of consent to trial participation ............................26
3.3.4.3
Discontinuation of the trial by the sponsor..............................26
3.3.5
Replacement of subjects .......................................................................26
4.
TREATMENTS........................................................................................ 27
4.1
INVESTIGATIONAL TREATMENTS ..........................................................27
4.1.1
Identity of the Investigational Medicinal Products ...........................27
4.1.2
Selection of doses in the trial................................................................28
4.1.3
Method of assigning subjects to treatment groups ............................28
4.1.4
Drug assignment and administration of doses for each subject .......29
4.1.5
Blinding and procedures for unblinding ............................................29
4.1.6
Packaging, labelling, and re-supply ....................................................30
4.1.7
Storage conditions.................................................................................30
4.1.8
Drug accountability ..............................................................................30
4.2
OTHER TREATMENTS, EMERGENCY  PROCEDURES,
RESTRICTIONS ...............................................................................................31
4.2.1
Other treatments and emergency procedures....................................31
4.2.2
Restrictions............................................................................................31
4.2.2.1
Restrictions regarding concomitant treatment .........................31
4.2.2.2
Restrictions on diet and life style.............................................31
4.3
TREATMENT COMPLIANCE.......................................................................32
5.
ASSESMENTS ......................................................................................... 33
5.1
ASSESSMENT OF EFFICACY.......................................................................33
5.2
ASSESSMENT OF SAFETY............................................................................33
5.2.1
Physical examination ............................................................................33
5.2.2
Vital signs...............................................................................................33
5.2.3
Safety laboratory parameters..............................................................33
5.2.4
Electrocardiogram................................................................................36
5.2.5
Other safety parameters.......................................................................36
5.2.6
Assessment of adverse events...............................................................36
5.2.6.1
Definitions of adverse events...................................................36
Adverse event ............................................................36
5.2.6.1.1
Serious adverse event ................................................37
5.2.6.1.2
AEs considered ‘Always Serious’.............................37
5.2.6.1.3
Adverse events of special interest .............................38
5.2.6.1.4
Intensity (severity) of AEs.........................................38
5.2.6.1.5
Causal relationship of AEs ........................................38
5.2.6.1.6
5.2.6.2
Adverse event collection and reporting ...................................39


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 8 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
AE collection.............................................................39
5.2.6.2.1
AE reporting to the sponsor and timelines ................40
5.2.6.2.2
Information required..................................................40
5.2.6.2.3
Pregnancy ..................................................................40
5.2.6.2.4
5.3
DRUG CONCENTRATION MEASUREMENTS AND 
PHARMACOKINETICS..................................................................................41
5.3.1
Assessment of pharmacokinetics .........................................................41
5.3.2
Methods of sample collection...............................................................41
5.3.2.1
Blood sampling for pharmacokinetic analysis of BI 1323495.41
5.3.2.2
Blood sampling for pharmacokinetic analysis of itraconazole 41
5.3.3
Analytical determinations ....................................................................42
5.3.3.1
Analytical determination of analyte plasma concentration......42
5.3.3.2
Further use of plasma samples.................................................42
5.4
BIOBANKING ...................................................................................................42
5.6
APPROPRIATENESS OF MEASUREMENTS.............................................43
6.
INVESTIGATIONAL PLAN.................................................................. 44
6.1
VISIT SCHEDULE............................................................................................44
6.2
DETAILS OF TRIAL PROCEDURES AT SELECTED VISITS ................44
6.2.1
Screening period....................................................................................44
6.2.2
Treatment periods.................................................................................44
6.2.3
Follow-up period and trial completion ...............................................45
7.
STATISTICAL METHODS AND DETERMINATION OF
SAMPLE SIZE......................................................................................... 46
7.1
STATISTICAL DESIGN – MODEL ...............................................................46
7.2
NULL AND ALTERNATIVE HYPOTHESES ..............................................46
7.3
PLANNED ANALYSES....................................................................................46
7.3.1
Primary endpoint analyses...................................................................47
7.3.2
Secondary endpoint analyses ...............................................................48
7.3.4
Safety analyses.......................................................................................49
7.4
INTERIM ANALYSES .....................................................................................49
7.5
HANDLING OF MISSING DATA ..................................................................50
7.5.1
Safety......................................................................................................50
7.5.2
Pharmacokinetics..................................................................................50
7.6
RANDOMISATION ..........................................................................................50
7.7
DETERMINATION OF SAMPLE SIZE ........................................................50


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 9 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
8.
INFORMED CONSENT, TRIAL RECORDS, DATA 
PROTECTION, PUBLICATION POLICY, AND 
ADMINISTRATIVE STRUCTURE...................................................... 52
8.1
TRIAL APPROVAL, SUBJECT INFORMATION, INFORMED 
CONSENT ..........................................................................................................52
8.2
DATA QUALITY ASSURANCE .....................................................................53
8.3
RECORDS..........................................................................................................53
8.3.1
Source documents .................................................................................53
8.3.2
Direct access to source data and documents.......................................54
8.3.3
Storage period of records.....................................................................54
8.4
EXPEDITED REPORTING OF ADVERSE EVENTS .................................55
8.5
STATEMENT OF CONFIDENTIALITY AND SUBJECT PRIVACY.......55
8.5.1
Collection, storage and future use of biological samples and 
corresponding data ...............................................................................55
8.6
TRIAL MILESTONES .....................................................................................55
8.7
ADMINISTRATIVE STRUCTURE OF THE TRIAL ..................................56
9.
REFERENCES......................................................................................... 58
9.1
PUBLISHED REFERENCES...........................................................................58
9.2
UNPUBLISHED REFERENCES.....................................................................60
10. APPENDICES .......................................................................................... 61
11. DESCRIPTION OF GLOBAL AMENDMENT(S).............................. 62
11.1
GLOBAL AMENDMENT 1 .............................................................................62


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 10 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
ABBREVIATIONS
ADME
Absorption, distribution, metabolism, and excretion
AE
Adverse event
AESI
Adverse events of special interest
ANOVA
Analysis of variance
AUC0-∞
Area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 extrapolated to infinity
AUC0-tz
Area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 to the last quantifiable data point
AUC0-24
Area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 to 24 hours after drug administration
BI
Boehringer Ingelheim
BMI
Body mass index (weight divided by height squared)
BP
Blood pressure
CA
Competent authority
CI
Confidence interval
Cmax
Maximum measured concentration of the analyte in plasma
COPD
Chronic obstructive pulmonary disease 
CRF
Case Report Form, paper or electronic (sometimes referred to as ‘eCRF’)
CTP
Clinical trial protocol
CTR
Clinical trial report
CYP
Cytochrome P450
DILI
Drug induced liver injury
ECG
Electrocardiogram
eCRF
Electronic case report form
ED50
Effective dose at 50% reduction
eDC
Electronic data capture 
EDTA
Ethylenediaminetetraacetic acid
EM
Extensive metabolizer
EoTrial
End of trial
EudraCT
European Clinical Trials Database
FU
Follow-up
GCP
Good Clinical Practice


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 11 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
gCV
Geometric coefficient of variation
gMean
Geometric mean
HPC
Human Pharmacology Centre
HR
Heart rate
IB
Investigator’s brochure
IC50
Half-maximal inhibitory concentration
IEC
Independent Ethics Committee
IPD
Important protocol deviation
IRB
Institutional Review Board
ISF
Investigator site file
LC-MS/MS
Liquid chromatography with tandem mass spectrometry
MDA
Methylenedioxyamphetamine
MDMA
Methylenedioxymethamphetamine
MedDRA
Medical Dictionary for Regulatory Activities
NOAEL
No observed adverse effect level
P-gp
P-glycoprotein
PK
Pharmacokinetic(s)
PKS
Pharmacokinetic set
PP
Polypropylene
PR
Pulse rate
QT
Time between start of the Q-wave and the end of the T-wave in an 
electrocardiogram
QTc
QT interval corrected for heart rate using the method of Fridericia (QTcF) 
or Bazett (QTcB)
R
Reference treatment
REP
Residual effect period
SAE
Serious adverse event
SCR
Screening
SmPC
Summary of Product Characteristics
SOP
Standard operating procedure
SRD
Single-rising dose
T
Test product or treatment
tmax
Time from (last) dosing to the maximum measured concentration of the 
analyte in plasma
TS
Treated set


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 12 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
tz
Time of last measurable concentration of the analyte in plasma
TSAP
Trial statistical analysis plan
ULN
Upper limit of normal
XTC
Ecstasy 


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 13 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
1.
INTRODUCTION
This trial will be performed to investigate the relative bioavailability of BI 1323495 in plasma 
when given alone compared to when given together with the CYP3A and P-glycoprotein 
inhibitor itraconazole.
1.1
MEDICAL BACKGROUND
1.2
DRUG PROFILE
1.2.1
BI 1323495


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 14 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
For a detailed description of the BI 1323495 profile, please refer to the current Investigator’s 
Brochure (IB) (c21238478). 
At the time of preparing this trial protocol, two Phase I studies with administration of BI 
1323495 to healthy male volunteers have been completed, trial 1405-0001 (first-in-man trial,
in reporting phase) and study 1405-0007 (relative BA/food effect, in evaluation phase).
In the single rising dose (SRD) trial 1405-0001, single-dose treatment with up to 600 mg BI 
1323495 or placebo was safe and well tolerated. There was no relationship between the 
occurrence of AEs and dose. 
 
For details on safety and tolerability as well as on pharmacokinetics and biomarker data of 
the SRD trial refer to the IB (c21238478).


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 15 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
The clinical part of the food effect trial 1405-0007, a randomised 2-way crossover study to 
compare the relative bioavailability of a single dose of 100 mg BI 1323495 (50 mg tablet) 
administered in the fasted state versus fed state (high-fat) conditions, has been completed and 
data are currently under evaluation.
1.2.2
Itraconazole
Absorption of itraconazole solution is fast with maximum plasma concentration being 
reached within 2.5 h after oral administration in fasting condition. Bioavailability of 
itraconazole liquid increases by 30% when given under fasting condition compared to 
administration together with food (R18-2644). Mean peak plasma concentrations were 547.7 
ng/mL after a single dose of 200 mg itraconazole solution (fasting) and 1965 ng/mL after 15 
days of daily treatment with 200 mg itraconazole solution (fasting). Pharmacokinetics of 
itraconazole is non-linear. The half-life of itraconazole after multiple doses of 200 mg once 
daily with solution formulation was about 40 h (R17-3742).
In the liver, itraconazole is metabolised extensively to more than 30 metabolites (R17-3743). 
Its main metabolite, OH-itraconazole, accounts for about twice the concentration of plasma 
itraconazole at trough. It has been shown in vitro that CYP3A4 is mainly responsible for the 
formation of this metabolite [R18-2644]. FDA classifies itraconazole as strong index 
inhibitor of CYP3A and as inhibitor of P-glycoprotein (P-gp) (R18-0241). However, not only 
itraconazole contributes to the in vivo inhibition of CYP3A observed after itraconazole 
administration but also three of its metabolites (OH-itraconazole, keto-itraconazole, and N 
desalkyl-itraconazole) (R10-1102).
For a more detailed description of itraconazole, please refer to the German Summary of 
Product Characteristics (SmPC) for Sempera® Liquid 10 mg/ml [R18-2644] and the UK 
SmPC for Sporanox® 10 mg/ml Oral Solution (R18-2643).
1.2.3
Residual Effect Period
The Residual Effect Period (REP, i.e., the period after the last dose with measurable drug 
levels and/or pharmacodynamic effects still likely to be present) of BI 1323495 is 
approximately 7 days.
When given together with itraconazole (Treatment T), it is expected that plasma exposure of 
BI 1323495 could be increased (albeit within the exposures explored in the clinical trial 
1405-0001), and the time of relevant plasma exposure could be prolonged. This might result 
in a prolonged period in which adverse effects could potentially occur. 


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 16 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
For the use of itraconazole in Treatment T, the REP is defined as 9 days after last 
administration of itraconazole on Day 7 in Period 2.
1.3
RATIONALE FOR PERFORMING THE TRIAL
in this trial, the focus is on the DDI victim potential of BI 1323495 with regard to 
CYP3A4 and P-gp inhibition as this may lead to clinically relevant increases in exposures 
with potential impact on patient safety.
Itraconazole is chosen for this trial as perpetrator drug, as this drug is recommended as strong 
inhibitor of CYP3A by EMA (P15-06991), as strong index inhibitor of CYP3A by FDA 
(R18-0241), and as strong inhibitor of CYP3A by PMDA (P15-06298) and it is an inhibitor 
of P-gp (R18-0241). Moreover, safety and tolerability of itraconazole were acceptable in 
previous drug-drug interaction trials (c02336088, c03355329, c08928447).
1.4
BENEFIT - RISK ASSESSMENT
Participation in this clinical trial is without any (therapeutic) benefit for healthy subjects. 
Their participation, however, is of major importance for the development of a new orally 
available drug, which might improve the therapy in patients with COPD and emphysema.
Subjects are exposed to risks of study procedures and risks related to the exposure to the trial 
medication.
1.4.1
Procedure-related risks
The use of an indwelling venous catheter or venepuncture for e.g. blood sampling may result 
in mild bruising, and in rare cases, in transient inflammation of the wall of the vein, or nerve 
injury, potentially resulting in paraesthesia, reduced sensibility, and/or pain for an indefinite 
period, as well as in feeling of lightheadedness or in syncope.
The total volume of blood withdrawn per subject during the entire study will not exceed the 
volume of a normal blood donation (500 mL). No health-related risk to healthy subjects is 
expected from withdrawal of this volume of blood.
1.4.2
Drug-related risks and safety measures
1.4.2.1
Drug-induced liver injury
Although rare, a potential for drug-induced liver injury (DILI) is under constant surveillance 
by sponsors and regulators. Therefore, this trial requires timely detection, evaluation, and 
follow-up of laboratory alterations in selected liver laboratory parameters to ensure subjects´ 
safety; see also Section 5.2.6.1.4, adverse events of special interest.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 17 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
1.4.2.2
BI 1323495


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 18 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
In the SRD and food effect trial, single dose administration of BI 1323495 up to 600 mg was 
well tolerated, with no clinically relevant changes in safety lab, ECG, and vital signs 
observed (ref. Section 1.2.1).
As with all drugs, the potential for hypersensitivity and allergic reactions has to be taken into 
consideration when BI 1323495 is administered.
1.4.2.3
Itraconazole
In this trial itraconazole will be used in a standard clinical dose of 200 mg once daily for 10
days. Multiple dosing of 200 mg itraconazole up to 15 days was of acceptable tolerability in 
healthy subjects (c02336088, c03355329, c08928447, R17-3742). 
For a detailed description of the potential risks of itraconazole treatment, please refer to the 
German Summary of Product Characteristics (SmPC) for Sempera® Liquid 10 mg/ml (R18-
2644).
In order to address the risk of hepatotoxicity, only subjects with normal liver enzyme values 
will be included into the study. Safety laboratory parameters will be monitored closely. 
An individual subject will be removed from the trial if the subject shows an elevation of AST 
and/or ALT ≥3-fold ULN combined with an elevation of total bilirubin ≥2-fold ULN 
(measured in the same blood sample, see Section 3.3.4.1). 
Further, most of the reported cases of serious hepatotoxicity during itraconazole treatment 
occurred in patients that suffered from concomitant liver diseases, had other significant 
diseases, or took concomitant hepatotoxic drugs. Subjects with liver diseases or a medical 
history of drug-induced liver failure are excluded from trial participation.
Itraconazole has shown a dose-related increase in maternal toxicity, embryotoxicity and 
teratogenicity in nonclinical studies at high doses, and therefore itraconazole must not be 
used during pregnancy. Woman of childbearing potential have to use a highly effective 
method of contraception until the menstrual period after the last itraconazole dose (R18-2644, 
R18-2643). For risk mitigation, only male subjects will be included into this clinical trial.
Considering these safety measures and taking into account the reported acceptable tolerability 
of itraconazole, the planned administration of itraconazole does not represent an undue risk to 
healthy male volunteers.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 19 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
1.4.2.4
Potential interaction between itraconazole and BI 1323495
It is likely that concomitant administration of BI 1323495 with itraconazole may cause an 
increase of plasma concentrations and t1/2 of BI 1323495. The effect of itraconazole in 
increasing Cmax and AUC of other drugs can be as high as 3.4-fold and 11-fold, respectively, 
as seen with oral midazolam, a sensitive CYP3A4 substrate, when co-administered with oral 
itraconazole 200 mg/d (R01-0516, R18-2644). Inhibition of P-gp may increase exposure of 
sensitive P-gp substrates like fexofenadine by factor 3-4 (R08-1652, P07-13746) and increase 
digoxin exposure by ~1.7-fold (R15-3252). Therefore, a low dose of 
 BI 1323495 has 
been selected for this trial (see Section 4.1.2).
1.4.2.5
Safety Measures

Careful selection of trial population with compound-specific exclusion criteria (see 
Section 3.3.3)

In-house confinement up to at least 24 hours in period 1 and up to at least 34 hours in 
period 2, respectively, to cover the period of high plasma exposures

Safety surveillance with close monitoring for possible changes in safety lab
1.4.2.6
Benefit –Risk Assessment Summary
In summary, BI 1323495 has the potential to become an oral treatment for patients with 
COPD. Based upon preclinical and clinical data with BI 1323495 and clinical information 
from competitor compounds as well as the implemented safety measures described above, 
healthy subjects will not be exposed to undue risks in relation to the important information 
expected from this trial as a basis for further clinical development of this compound. 
Healthy volunteers are not expected to have any direct benefit from participation in this drug-
drug-interaction (DDI) trial with BI 1323495 and itraconazole. 
Considering the medical need of the development of an effective treatment to slow the 
progression of COPD for patients with this disease, the Sponsor considers that the benefit 
outweighs the potential risks and justifies exposure of healthy male volunteers.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 20 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
2.
TRIAL OBJECTIVES AND ENDPOINTS
2.1
MAIN OBJECTIVES, PRIMARY AND SECONDARY ENDPOINTS
2.1.1
Main objectives
The main objective of this trial is to investigate the relative bioavailability of BI 1323495 in 
plasma when given as oral single dose together with multiple oral doses of itraconazole (Test, 
T) as compared to when given alone as oral single dose (Reference, R).
2.1.2
Primary endpoints
The following pharmacokinetic parameters will be determined for BI 1323495:

AUC0-tz (area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 to the last quantifiable data point)

Cmax (maximum measured concentration of the analyte in plasma)
2.1.3
Secondary endpoint
The following pharmacokinetic parameter will be determined for BI 1323495:

AUC0-∞(area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 extrapolated to infinity)


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 21 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
2.2.2.2
Safety and tolerability
Safety and tolerability of the trial treatments will be assessed based on:  

Adverse events (including clinically relevant findings from the physical examination)

Safety laboratory tests

12-lead ECG

Vital signs (blood pressure, pulse rate)


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 22 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
3.
DESCRIPTION OF DESIGN AND TRIAL POPULATION
3.1
OVERALL TRIAL DESIGN AND PLAN
The study will be performed as an open-label, two-treatment, two-period, one-way crossover
trial in healthy male subjects in order to compare the test treatment (T) to the reference 
treatment (R). The treatments will be one oral single dose of 
 BI 1323495 administered 
as tablet formulation together with multiple oral doses of 200 mg itraconazole as oral solution 
formulation (concentration: 10 mg/mL) (T) and one single dose of 
 BI 1323495 as 
tablet formulation given alone (R).
In both treatments, BI 1323495 is administered to subjects in the fasting state. In the first 
treatment period (Period 1, Visit 2), all subjects are planned to undergo treatment R, and in 
the second treatment period (Period 2, Visit 3), all subjects are planned to undergo treatment 
T. For details, refer to Section 4.1.
There will be a washout period of at least 7 days between the administrations of BI 1323495.
Figure 3.1: 1
Trial design
An overview of all relevant trial activities is provided in the Flow Chart. For visit schedule 
and details of trial procedures at selected visits, refer to Sections 6.1 and 6.2, respectively.
3.2
DISCUSSION OF TRIAL DESIGN, INCLUDING THE CHOICE OF 
CONTROL GROUPS
For relative bioavailability trials, the crossover design is preferred because of its efficiency: 
since each subject serves as his/her own control, the comparison between treatments is based 
on an intra-subject comparison, thus removing inter-subject variability from the comparison 
between treatments (R94-1529). Because of the long half-life (about 40 h) of itraconazole and 
its metabolites, a fixed sequence design was selected, with administration of itraconazole in 
the second study period only. This design is not expected to lead to systematic errors in the 
estimation of the treatment effects since nonspecific time-effects are unlikely due to the short 
trial duration. For itraconazole studies, this design is recommended by the Innovation and 
Screening
Period 1
Period 2
End-of-trial
BI 1323495
Itraconazole
≥1 day


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 23 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Quality in Pharmaceutical Development’s Clinical Pharmacology Leadership Group (CPLG)
(R17-3744).
For this PK drug-drug interaction trial, open-label treatment is acceptable, because the 
primary and secondary endpoints of this trial are PK endpoints derived from measurement of 
plasma concentrations of BI 1323495. These endpoints are not expected to be affected by 
knowledge of treatment.
3.3
SELECTION OF TRIAL POPULATION
It is planned that 14 healthy male subjects will enter the study. They will be recruited from 
the volunteers' pool of the trial site.
Due to the reproduction toxicity itraconazole has shown in nonclinical studies, only male 
subjects will be included in this trial.
A log of all subjects enrolled into the trial (i.e. who have signed informed consent) will be 
maintained in the ISF irrespective of whether they have been treated with investigational drug 
or not.
3.3.1
Main diagnosis for trial entry
The study will be performed in healthy subjects.
3.3.2
Inclusion criteria
Subjects will only be included in the trial if they meet the following criteria:
1. Healthy male subjects according to the assessment of the investigator, as based on a 
complete medical history including a physical examination, vital signs (BP, PR), 12-lead 
ECG, and clinical laboratory tests
2. Age of 18 to 50 years (inclusive)
3. BMI of 18.5 to 29.9 kg/m2 (inclusive)
4. Signed and dated written informed consent prior to admission to the study, in accordance 
with GCP and local legislation
3.3.3
Exclusion criteria
Subjects will not be allowed to participate, if any of the following general criteria apply:
1. Any finding in the medical examination (including BP, PR, or ECG) deviating from 
normal and assessed as clinically relevant by the investigator
2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, 
diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the 
range of 45 to 90 bpm
3. Any laboratory value outside the reference range that the investigator considers to be of 
clinical relevance


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 24 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator
5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological,
blood coagulation, or hormonal disorders
6. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the 
pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
7. Diseases of the central nervous system (including but not limited to any kind of seizures 
or stroke), and other relevant neurological or psychiatric disorders 
8. History of relevant orthostatic hypotension, fainting spells, or blackouts
9. Chronic or relevant acute infections
10. History of relevant allergy or hypersensitivity (including allergy to the trial medication or 
its excipients) 
11. Use of drugs within 30 days of planned administration of trial medication that might 
reasonably influence the results of the trial (including drugs that cause QT/QTc interval
prolongation)
12. Intake of an investigational drug in another clinical trial within 60 days of planned 
administration of investigational drug in the current trial, or concurrent participation in 
another clinical trial in which investigational drug is administered
13. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
14. Inability to refrain from smoking on specified trial days
15. Alcohol abuse (consumption of more than 24 g per day)
16. Drug abuse or positive drug screening
17. Blood donation of more than 100 mL within 30 days of planned administration of trial 
medication or intended blood donation during the trial
18. Intention to perform excessive physical activities within one week prior to the 
administration of trial medication or during the trial
19. Inability to comply with the dietary regimen of the trial site
20. A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are 
repeatedly greater than 450 ms) or any other relevant ECG finding at screening
21. A history of additional risk factors for Torsade de Pointes (such as heart failure, 
hypokalaemia, or family history of Long QT Syndrome)
22. Subject is assessed as unsuitable for inclusion by the investigator, for instance, because 
the subject is not considered able to understand and comply with study requirements, or 
has a condition that would not allow safe participation in the study 
23. Current or history of relevant kidney, urinary tract diseases or abnormalities (e.g. 
nephrolithiasis, hydronephrosis, acute or chronic nephritis, renal injury, renal failure)
24. Estimated glomerular filtration rate according to CKD-EPI formula < 90 mL/min at 
screening
25. Within 10 days prior to administration of trial medication, use of any drug that could 
reasonably inhibit platelet aggregation or coagulation (e.g., acetylsalicylic acid)
26. History of drug induced liver injury


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 25 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
27. Liver enzymes (ALT, AST, GGT) above upper limit of normal at the screening 
examination
28. History of heart failure, or any evidence of ventricular dysfunction 
29. Known sorbitol/polyols intolerance
30. Subjects with female partner of childbearing potential who are unwilling to use male 
contraception (condom or sexual abstinence) from first administration until 30 days after 
last administration of trial medication
For study restrictions, refer to Section 4.2.2.
3.3.4
Withdrawal of subjects from treatment or assessments
Subjects may discontinue trial treatment or withdraw consent to trial participation as a whole 
(‘withdrawal of consent’) with very different implications; please see Sections 3.3.4.1 and 
3.3.4.2 below.
If a subject is removed from or withdraws from the trial prior to the first administration of 
trial medication, the data of this subject will not be entered in the case report form (CRF) and 
will not be reported in the clinical trial report (CTR). If a subject is removed from or 
withdraws from the trial after the first administration of trial medication, this will be 
documented and the reason for discontinuation must be recorded in the CRF; in addition, the 
data will be included in the CRF and will be reported in the CTR. At the time of 
discontinuation, a complete end of trial examination will be performed, if possible, and the 
information will be recorded in the CRF. If the discontinuation occurs before the end of the 
REP (see Section 1.2.3), the discontinued subject should, if possible, be questioned for AEs 
and concomitant therapies at or after the end of the REP in order to ensure collection of AEs 
and concomitant therapies throughout the REP, if not contrary to any consent withdrawal of 
the subject.
3.3.4.1
Discontinuation of trial treatment
An individual subject will discontinue trial treatment if:
1. The subject wants to discontinue trial treatment, without the need to justify the decision
2. The subject has repeatedly shown to be non-compliant with important trial procedures 
and, in the opinion of both, the investigator and sponsor representative, is not willing or 
able to adhere to the trial requirements in the future.
3. The subject needs to take concomitant medication that interferes with the investigational 
medicinal product or other trial treatment
4. The subject can no longer receive trial treatment for medical reasons (such as surgery, 
adverse events [AEs], or diseases)
5. The subject experiences a serious adverse drug reaction or a non-serious adverse drug
reaction of severe intensity
6. The subject has an elevation of AST and/or ALT ≥3-fold ULN
7. The subject has an elevation of AST and/or ALT ≥3-fold ULN and an elevation of total 
bilirubin ≥2-fold ULN (measured in the same blood sample) and/or needs to be followed 


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 26 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
up according to the DILI checklist provided in the ISFIn addition to these criteria, the 
investigator may discontinue subjects at any time based on his or her clinical judgment.
Even if the trial treatment is discontinued, the subject remains in the trial and, given his/her 
agreement, will undergo the procedures for early treatment discontinuation and follow up as 
outlined in the Flow Chart and section 6.2.3.
3.3.4.2
Withdrawal of consent to trial participation
Subjects may withdraw their consent to trial participation at any time without the need to 
justify the decision. If a subject wants to withdraw consent, the investigator should be 
involved in the discussion with the subject and explain the difference between trial treatment 
discontinuation and withdrawal of consent to trial participation, as well as explain the options 
for continued follow up after trial treatment discontinuation, please see Section 3.3.4.1 above
3.3.4.3
Discontinuation of the trial by the sponsor
Boehringer Ingelheim reserves the right to discontinue the trial at any time for any of the 
following reasons:
1. Failure to meet expected enrolment goals 
2. New toxicological findings, serious adverse events, or any safety information invalidating
the earlier positive benefit-risk-assessment. More specifically, the trial will be terminated 
if more than 50% of the subjects have drug-related and clinically relevant adverse events 
of moderate or severe intensity, if more than two subjects have drug related non-serious 
adverse events of severe intensity or if at least 1 drug-related serious adverse event is 
reported.
3. Violation of GCP or the CTP impairing the appropriate conduct of the trial
4. The sponsor decides to discontinue the further development of the investigational product
3.3.5
Replacement of subjects
Subjects withdrawn due to drug related adverse events will not be replaced. In case more than
2 subjects do not complete the trial, the Clinical Trial Leader together with the Trial 
Pharmacokineticist and the Trial Statistician are to decide, if and how many subjects will be 
replaced. A replacement subject will be assigned a unique trial subject number.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 27 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
4.
TREATMENTS
4.1
INVESTIGATIONAL TREATMENTS
The investigational product BI 1323495 as tablet formulation has been manufactured by BI 
Pharma GmbH & Co. KG. Itraconazole oral solution will be obtained from a public 
pharmacy.
4.1.1
Identity of the Investigational Medicinal Products
The characteristics of the test products are given below:
Test product 1
Substance:
BI 1323495
Pharmaceutical formulation: Tablet, film-coated
Source:
BI Pharma GmbH & Co. KG, Germany
Unit strength:
Posology:
1-0-0
Route of administration:
Oral
Duration of use:
Single dose in treatments R and T
Test product 2
Name:
Sempera® Liquid 10 mg/mL 
Substance:
Itraconazole
Pharmaceutical formulation: Oral solution
Source:
Public pharmacy
Holder of marketing
authorisation:
Janssen-Cilag GmbH, Neuss, Germany
Unit strength:
10 mg/mL
Posology:
20 mL-0-0
Route of administration:
Oral
Duration of use:
10 days in treatment T


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 28 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
4.1.2
Selection of doses in the trial
Perpetrator (itraconazole)
The dose of itraconazole selected for this trial reflects standard clinical doses, is considered 
sufficient to yield significant CYP3A and P-gp inhibition and has been used successfully and 
safely in previous drug-drug-interaction trials (c02336088, c03355329, c08928447).
Victim (BI 1323495)
For the current trial, a dose of 
 BI 1323495 is selected, in order to ensure that BI 
1323495 plasma concentrations, even in case of a substantial increase when given with 
itraconazole, are within the range of concentrations that were explored in the SRD trial 1405-
0001 and that were associated with good safety and tolerability (ref. Section 1.4.2.4).
4.1.3
Method of assigning subjects to treatment groups
There is only one treatment sequence investigated in this trial, and each subject will be
allocated to the same treatment sequence (R-T). The subjects will be allocated to a study
subject number by drawing lots prior to first administration of trial medication in the morning
of Day 1 of Visit 2. Once a subject number has been assigned, it cannot be reassigned to any
other subject.
All subjects may be treated in one cohort, i.e. all subjects may receive treatment on the same
calendar day. In case this is not feasible (e.g., due to logistical or recruitment reasons), the


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 29 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
group may be split into several cohorts as required. Treatment of all subjects on the same
calendar day is acceptable (for safety margin to exposure reached in previous SRD trial 1405-
0001 refer to Section 1.4.2; for discussion of study-associated risks and safety measures see
Section 1.4.1).
4.1.4
Drug assignment and administration of doses for each subject
This trial is a one-way crossover study. All subjects will receive the 2 treatments in fixed
order. The treatments to be evaluated are outlined in Table 4.1.4: 1 below. 
Table 4.1.4: 1
Dosage and treatment schedule
Treatment 
period
Treatment
Substance
Formulation
Unit 
strength
Dosage
Total  
dose
1
R (Reference)
BI 1323495
Tablet, 
film-coated
1 tablet as single dose
(Day 1)
2
T (Test)
BI 1323495
Itraconazole
Tablet, 
film-coated
Oral solution
10 mg/mL
1 tablet as single dose
(Day 1)
20 mL (200 mg) qd for 10 days 
(Days -3 to 7)
2000 mg
Administration of trial medication will be performed after subjects have fasted overnight; 
fasting is to start no later than 10 h before the scheduled dosing of BI 1323495 or 9 hours 
before itraconazole administration. The investigator (or authorised designee) will administer 
the trial medication as an oral dose together with about 240 mL of water to subjects who are 
in a standing position. For drug administration, the so-called four-eye principle (two-person 
rule) should be applied. For this, one authorised employee of the trial site should witness the 
administration of trial medication, and – if applicable – its preparation (e.g. reconstitution), if 
correct dosage cannot be ensured otherwise.
Subjects will be kept under close medical surveillance until at least 24 hours after
administration of BI 1323495 in each period. During the first 4 h after administration of 
BI 1323495, subjects are not allowed to lie down (i.e. no declination of the upper body of 
more than 45 degrees from upright posture).
The treatments with BI 1323495 will be separated by a wash-out phase of at least 7 days.
4.1.5
Blinding and procedures for unblinding
This Phase I trial will be handled in an open fashion throughout (that is, during the conduct,
including data cleaning and preparation of the analysis). This is considered acceptable 
because the potential for bias seems to be low and does not outweigh practical considerations.
Emergency envelopes will not be provided, because the dose of trial medication is known to 
investigators and subjects.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 30 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
4.1.6
Packaging, labelling, and re-supply
BI 1323495 tablets
BI 1323495 tablets will be provided by BI. They will be packaged and labelled in accordance 
with local law and the principles of Good Manufacturing Practice. For details of packing and 
the description of the label, refer to the ISF.
The telephone number of the sponsor and the name, address and telephone number of the trial 
site are provided in the subject information form. The EudraCT number is indicated on the 
title page of this protocol as well as on the subject information and informed consent forms. 
No re-supply is planned.
Itraconazole oral solution
Itraconazole oral solution will be obtained by the clinical trial site from a public pharmacy. 
The drug will be dispensed out of the original, unmodified packages.
4.1.7
Storage conditions
Drug supplies will be kept in their original packaging and in a secure limited access storage 
area in accordance with the recommended (labelled) storage conditions. If necessary, a 
temperature log must be maintained to make certain that the drug supplies are stored at the 
correct temperature. If the storage conditions are found to be outside the specified range, the 
local clinical monitor (as provided in the list of contacts) is to be contacted immediately.
4.1.8
Drug accountability
The investigator or designee will receive the investigational drugs delivered from the sponsor
following requirements are fulfilled:

Approval of the clinical trial protocol by the IRB / ethics committee

Approval/notification of the regulatory authority, e.g. competent authority

Availability of the curriculum vitae of the Principal Investigator

Availability of a signed and dated clinical trial protocol  
Only authorised personnel documented in the form 'Trial Staff List' may dispense medication 
to trial subjects. The trial medication must be administered in the manner specified in the 
CTP.
The investigator or designee must maintain records of the product’s delivery to the trial site, 
the inventory at the site, the use by each subject, and the disposal of unused products.These 
records will include dates, quantities, batch / serial numbers, expiry ('use-by') dates, and the 
unique code numbers assigned to the investigational medicinal product and trial subjects. The 
investigator or designee will maintain records that document adequately that the subjects 
were provided the doses specified by the CTP and reconcile all investigational medicinal 
products received from the sponsor. At the time of disposal of remaining trial medication, the 
investigator or designee must verify that no remaining supplies are in the investigator’s 
possession.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 31 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
All unused medication will be disposed of locally by the trial site upon written authorisation 
of the Clinical Trial Leader. Receipt, usage and disposal of trial medication must be 
documented on the appropriate forms. Account must be given for any discrepancies.
4.2
OTHER TREATMENTS, EMERGENCY  PROCEDURES,
RESTRICTIONS
4.2.1
Other treatments and emergency procedures
There are no special emergency procedures to be followed. No additional treatment is 
planned. However, if adverse events require treatment, the investigator can authorise 
symptomatic therapy. In those cases, subjects will be treated as necessary and, if required, 
kept under supervision at the trial site or transferred to a hospital until all results of medical 
evaluations are acceptable.
4.2.2
Restrictions
4.2.2.1
Restrictions regarding concomitant treatment
In principle, no concomitant therapy is allowed. All concomitant or rescue therapies will be 
recorded (including time of intake on study days) on the appropriate pages of the CRF.
Known inhibitors/inducers of CYP3A and P-gp activity, drugs with a known hepatotoxicity 
profile, drugs which are contraindicated to be co-administered with itraconazole (ref. R18-
2644),
 
 should be avoided during the entire study; if necessary, short term use of 
ibuprofen is acceptable.
4.2.2.2
Restrictions on diet and life style
Poppy-seeds containing foods should not be consumed starting 3 days before the first drug 
administration in each treatment period, in order to avoid false-positive results in the drug-
screen.
While admitted to the trial site, the subjects will be instructed not to consume any foods or 
drinks other than those provided by the staff. Standardised meals will be served at the times
indicated in the Flow Chart.
No food is allowed within 10 h before and for at least 4 h after intake of BI 1323495. 
Subjects will be advised to not consume any food within 9 h before and 1 h after itraconazole 
administrations.
On Day 1, from 1 h before intake of BI 1323495 (Period 1) or itraconazole (Period 2), 
respectively, fluid intake is restricted to the water administered with the drug, and an 
additional 240 mL of water at 2 h and 4 h post-dose (mandatory for all subjects). From lunch 
until 23 h post-dose, total fluid intake is restricted to 3000 mL.
Grapefruits, Seville oranges (sour or bitter oranges) and their juices, and dietary supplements 
and products containing St. John's wort (Hypericum perforatum) are not permitted from 7 


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 32 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
days before the first administration of trial medication in Period 1 until after the last PK 
sample of Period 2 is collected. 
Alcoholic beverages are not permitted from 3 days before the first administration of trial 
medication in Period 1 until after the last PK sample in Period 2 is collected.
Methylxanthine-containing drinks or foods (such as coffee, tea, cola, energy drinks, or 
chocolate) are not allowed from 10 h before until 24 h after administration of BI 1323495.
Smoking is not allowed during in-house confinement.
Excessive physical activity (such as competitive sport) should be avoided from 7 days before 
the first administration of trial medication until the end of trial examination.
Direct exposure to the sun or exposure to solarium radiation should be avoided during the 
entire study.
4.3
TREATMENT COMPLIANCE
Compliance will be assured by administration of all trial medication in the study centre under 
supervision of the investigating physician or a designee. The measured plasma concentrations 
of trial medication will provide additional confirmation of compliance.
Subjects who are non-compliant (for instance, who do not appear for scheduled visits or 
violate trial restrictions) may be removed from the trial and the CRF will be completed 
accordingly (for further procedures, please see Section 3.3.4.1).


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 33 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
5.
ASSESMENTS
5.1
ASSESSMENT OF EFFICACY
Not applicable.
5.2
ASSESSMENT OF SAFETY
5.2.1
Physical examination
At screening, the medical examination will include demographics, height and body weight, 
smoking and alcohol history (results of alcohol history not mandatory to be entered into CRF 
or to be reported), relevant medical history and concomitant therapy, review of inclusion and 
exclusion criteria, review of vital signs (BP, PR), 12-lead ECG, laboratory tests, and a 
physical examination. At the end of trial examination, it will include review of vital signs, 12-
lead ECG, laboratory tests, and a physical examination.
5.2.2
Vital signs
Systolic and diastolic blood pressures (BP) as well as pulse rate (PR) or heart rate (heart rate 
is considered to be equal to pulse rate) will be measured by a blood pressure monitor 
(Dinamap Pro 100, GE Medical Systems, Freiburg, Germany) at the times indicated in the 
Flow Chart, after subjects have rested for at least 5 min in a supine position. All recordings 
should be made using the same type of blood pressure recording instrument on the same arm, 
if possible.
5.2.3
Safety laboratory parameters
For the assessment of laboratory parameters, blood and urine samples will be collected by the
trial site at the times indicated in the Flow Chart after the subjects have fasted for at least 
10 h. For retests, at the discretion of the investigator or designee, and for timepoints with 
liver function tests only (parameter set C) overnight fasting is not required.
The parameters that will be determined are listed in Tables 5.2.3: 1 and 5.2.3: 2. Reference 
ranges will be provided in the ISF, Section 10. 
Manual differential white blood cell count or urine sediment examinations will only be 
performed if there is an abnormality in the automatic blood cell count or in the urinalysis, 
respectively.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 34 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Table 5.2.3: 1
Routine laboratory tests
Functional lab group
BI test name [comment/abbreviation]
A1
B1
C1
D1
Haematology
Haematocrit
Haemoglobin
Red Blood Cell Count/Erythrocytes 
White Blood Cells/Leucocytes
Platelet Count/Thrombocytes (quant)
X
X
X
X
X
X
X
X
X
X
--
--
--
--
--
X
X
X
X
X
Automatic WBC 
differential, relative
Neutrophils/Leukocytes; Eosinophils/Leukocytes; Basophils/ 
Leukocytes; Monocytes/Leukocytes; 
Lymphocytes/Leukocytes 
X
X
--
X
Automatic WBC 
differential, absolute 
Neutrophil, absol.; Eosinophils, absol.; Basophils, absol.; 
Monocytes, absol.; Lymphocytes, absol.
X
X
--
X
Manual differential 
WBC2 (if automatic
differential WBC is 
abnormal)
Neut. Poly (segs); Neut. Poly (segs), absol.; Neutrophils 
Bands;  Neutrophils Bands, absol.; Eosinophils/Leukocytes; 
Eosinophils, absol.; Basophils/ Leukocytes; Basophils, absol.; 
Monocytes/ Leukocytes; Monocytes, absol.; 
Lymphocytes/Leukocytes; Lymphocytes, absol.
Coagulation
Activated Partial Thromboplastin Time 
Prothrombin time
INR (International Normalization Ratio)
Fibrinogen
X
X
X
X
--
--
--
X
--
--
--
--
X
X
X
X
Enzymes
AST [Aspartate transaminase] /GOT, SGOT 
ALT [Alanine transaminase] /GPT, SGPT
Alkaline Phosphatase
Gamma-Glutamyl Transferase)
Glutamate Dehydrogenase (GLDH)
Creatine Kinase [CK]
Creatine Kinase Isoenzyme MB [only if CK is elevated] 
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
--
--
X
X
X
X
X
X
X
Hormones
Thyroid Stimulating Hormone 
X
--
--
--
Substrates
Glucose (Plasma)
Creatinine
GFR/ CKD-EPI3
Bilirubin, Total 
Bilirubin, Direct
Protein, Total
C-Reactive Protein (Quant)  
Cholesterol, total 
Triglyceride
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
--
--
--
--
--
--
--
--
--
--
--
X
X
X
X
X
X
X
X
X
Electrolytes
Sodium
Potassium
X
X
X
X
--
--
X
X
1
A: parameters to be determined at Visit 1 (screening examination)
B: parameters to be determined at Visit 2 and 3 (for study days and time points refer to Flow Chart)
C: parameters to be determined at Visit 3 (for study days and time points refer to Flow Chart)
D: parameters to be determined at Visit 4 (end of trial examination)
2
Manual differential WBC if automatic differential WBC is abnormal
3
Estimated glomerular filtration rate according to CKD-EPI formula (R12-1392)


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 35 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Table 5.2.3: 1
Routine laboratory tests (cont.)
Functional lab group
BI test name [comment/abbreviation]
A1
B1
C1
D1
Urinalysis (Stix)
Urine Nitrite (qual)
Urine Protein (qual)
Urine Glucose (qual)
Urine Ketone (qual)
Urobilinogen (qual)
Urine Bilirubin (qual)
Urine RBC/Erythrocytes (qual)
Urine WBC/Leucocytes (qual)
Urine pH
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
--
--
--
--
--
--
--
--
--
X
X
X
X
X
X
X
X
X
Urine sediment2
Only positive findings will be reported (for instance, the 
presence of sediment bacteria, casts in sediment, squamous 
epithelial cells, erythrocytes, leukocytes)
1
A: parameters to be determined at Visit 1 (screening examination)
B: parameters to be determined at Visit 2 and 3 (for study days and time points refer to Flow Chart)
C: parameters to be determined at Visit 3 (for study days and time points refer to Flow Chart)
D: parameters to be determined at Visit 4 (end of trial examination)
2
Microscopic examination if erythrocytes, leukocytes, nitrite or protein in urinalysis are abnormal in urine
The tests listed in Table 5.2.3: 2 are exclusionary laboratory tests that may be repeated as 
required. The results will not be entered in the CRF/database and will not be reported in the 
CTR. Infectious serology is planned to perform these tests during screening only. Drug 
screening will be performed at screening and prior to first dose in each treatment period.
Table 5.2.3: 2
Exclusionary laboratory tests
Functional lab group
Test name 
Drug screening (urine)
Amphetamine/MDA
Barbiturates
Benzodiazepine
Cannabis
Cocaine 
Methadone
Methamphetamines/MDMA/XTC
Opiates 
Phencyclidine
Tricyclic antidepressants
Infectious serology (blood)
Hepatitis B surface antigen (qualitative)
Hepatitis B core antibody (qualitative)
Hepatitis C antibodies (qualitative)
HIV-1 and HIV-2 antibody (qualitative)
To encourage compliance with alcoholic restrictions, a breath alcohol test (e.g. Alcotest®
7410, Dräger AG, Lübeck, Germany) will be performed prior to first dose in each treatment 
period, and may be repeated at any time during the study at the discretion of an investigator 
or designee. The results will not be included in the CTR.
The laboratory tests listed in Tables 5.2.3: 1 and 5.2.3: 2 will be performed at 
 
 with the exception of 


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 36 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
drug screening. This test will be performed at the trial site using M-10/14-PDT test or a 
comparable test system.
Laboratory data will be transmitted electronically from the laboratory to the trial site.
5.2.4
Electrocardiogram
Twelve-lead ECGs (I, II, III, aVR, aVL, aVF, V1 - V6) will be recorded using a 
computerised electrocardiograph (CardioSoft EKG System, GE Medical Systems, Freiburg, 
Germany) at the times provided in the Flow Chart.
To achieve a stable heart rate at rest and to assure high quality recordings, the site personnel 
will be instructed to assure a relaxed and quiet environment, so that all subjects are at 
complete rest.
All ECGs will be recorded for 10 sec duration after subjects have rested for at least 5 min in a 
supine position. ECG assessment will always precede all other study procedures scheduled 
for the same time to avoid compromising ECG quality. 
All ECGs will be stored electronically on the Muse CV Cardiology System (GE Medical 
Systems, Freiburg, Germany). Electrode placement will be performed according to the 
method of Wilson, Goldberger and Einthoven modified by Mason and Likar (hips and 
shoulders instead of ankles and wrists). 
All locally printed ECGs will be evaluated by the investigator or a designee. Abnormal 
findings will be reported as AEs (during the trial) or baseline conditions (at screening) if 
assessed to be clinically relevant by the investigator. Any ECG abnormalities will be 
carefully monitored and, if necessary, the subject will be removed from the trial and will 
receive the appropriate medical treatment. 
ECGs may be repeated for quality reasons (for instance, due to alternating current artefacts, 
muscle movements, or electrode dislocation) and the repeated ECG will be used for analysis. 
Additional (unscheduled) ECGs may be collected by the investigator for safety reasons. 
5.2.5
Other safety parameters
Not applicable.
5.2.6
Assessment of adverse events
5.2.6.1
Definitions of adverse events
Adverse event
5.2.6.1.1
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical 
investigation subject administered a medicinal product and which does not necessarily have 
to have a causal relationship with this treatment.
An AE can therefore be any unfavourable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal 
product, whether or not considered related to the medicinal product.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 37 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
The following should also be recorded as an AE in the CRF and BI SAE form (if applicable):

Worsening of the underlying disease or of other pre-existing conditions 

Changes in vital signs, ECG, physical examination, and laboratory test results, if they 
are judged clinically relevant by the investigator
If such abnormalities already pre-exist prior to trial inclusion, they will be considered as 
baseline conditions and should be collected in the eCRF only.
Serious adverse event
5.2.6.1.2
A serious adverse event (SAE) is defined as any AE which fulfils at least one of the 
following criteria:

Results in death 

Is life-threatening, which refers to an event in which the patient was at risk of death 
at the time of the event; it does not refer to an event that hypothetically might have 
caused death if more severe 

Requires inpatient hospitalisation  

Requires prolongation of existing hospitalisation

Results in persistent or significant disability or incapacity 

Is a congenital anomaly/birth defect 

Is deemed serious for any other reason if it is an important medical event when based 
upon appropriate medical judgment which may jeopardise the patient and may 
require medical or surgical intervention to prevent one of the other outcomes listed in 
the above definitions. Examples of such events are intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalisation or development of dependency or 
abuse
AEs considered ‘Always Serious’
5.2.6.1.3
Cancers of new histology and exacerbations of existing cancer must be classified as a serious 
event regardless of the time since discontinuation of the trial medication and must be reported 
as described in 5.2.6.2, subsections ‘AE Collection’ and ‘AE reporting to sponsor and 
timelines’.
In accordance with the European Medicines Agency initiative on Important Medical Events, 
Boehringer Ingelheim has set up a list of further AEs, which, by their nature, can always be 
considered to be ‘serious’ even though they may not have met the criteria of an SAE as 
defined above.
The latest list of ‘Always Serious AEs’ can be found in the eDC system, an electronic data 
capture system which allows the entry of trial data at the trial site. These events should 
always be reported as SAEs as described above.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 38 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Adverse events of special interest
5.2.6.1.4
The term adverse events of special interest (AESI) relates to any specific AE that has been 
identified at the project level as being of particular concern for prospective safety monitoring 
and safety assessment within this trial, e.g. the potential for AEs based on knowledge from 
other compounds in the same class. AESIs need to be reported to the sponsor’s 
Pharmacovigilance Department within the same timeframe that applies to SAEs, please see 
section 5.2.6.2.2.
The following are considered as AESIs:

Hepatic injury
A hepatic injury is defined by the following alterations of hepatic laboratory 
parameters: 
o
An elevation of AST (aspartate transaminase) and/or ALT (alanine 
transaminase) ≥3-fold ULN combined with an elevation of total bilirubin 
≥2-fold ULN measured in the same blood sample, or
o
Aminotransferase (ALT, and/or AST) elevations ≥10 fold ULN
These lab findings constitute a hepatic injury alert and the subjects showing these lab 
abnormalities need to be followed up according to the ‘DILI checklist’ provided in the 
ISF. In case of clinical symptoms of hepatic injury (icterus, unexplained 
encephalopathy, unexplained coagulopathy, right upper quadrant abdominal pain, 
etc.) without lab results (ALT, AST, total bilirubin) available, the Investigator should 
make sure that these parameters are analysed, if necessary in an unscheduled blood 
test. Should the results meet the criteria of hepatic injury alert, the procedures 
described in the DILI checklist should be followed.
Intensity (severity) of AEs
5.2.6.1.5
The intensity (severity) of the AE should be judged based on the following:
Mild:
Awareness of sign(s) or symptom(s) that is/are easily tolerated
Moderate:
Sufficient discomfort to cause interference with usual activity
Severe:
Incapacitating or causing inability to work or to perform usual activities
Causal relationship of AEs
5.2.6.1.6
Medical judgment should be used to determine the relationship, considering all relevant 
factors, including pattern of reaction, temporal relationship, de-challenge or re-challenge, 
confounding factors such as concomitant medication, concomitant diseases and relevant 
history.
Arguments that may suggest that there is a reasonable possibility of a causal relationship 
could be:

The event is consistent with the known pharmacology of the drug 

The event is known to be caused by or attributed to the drug class

A plausible time to onset of the event relative to the time of drug exposure


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 39 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018

Evidence that the event is reproducible when the drug is re-introduced

No medically sound alternative aetiologies that could explain the event (e.g. pre-
existing or concomitant diseases, or co-medications)

The event is typically drug-related and infrequent in the general population not 
exposed to drugs (e.g. Stevens-Johnson syndrome)

An indication of dose-response (i.e. greater effect size if the dose is increased, smaller 
effect size if dose is reduced)
Arguments that may suggest that there is no reasonable possibility of a causal relationship 
could be:

No plausible time to onset of the event relative to the time of drug exposure is evident 
(e.g. pre-treatment cases, diagnosis of cancer or chronic disease within days / weeks 
of drug administration; an allergic reaction weeks after discontinuation of the drug 
concerned)

Continuation of the event despite the withdrawal of the medication, taking into 
account the pharmacological properties of the compound (e.g. after 5 half-lives). Of 
note, this criterion may not be applicable to events whose time course is prolonged 
despite removing the original trigger

Additional arguments amongst those stated before, like alternative explanation (e.g. 
situations where other drugs or underlying diseases appear to provide a more likely 
explanation for the observed event than the drug concerned)

Disappearance of the event even though the trial drug treatment continues or remains 
unchanged
5.2.6.2
Adverse event collection and reporting
AE collection
5.2.6.2.1
Upon enrolment into a trial, the subject’s baseline condition is assessed (for instance, by 
documentation of medical history/concomitant diagnoses), and relevant changes from 
baseline are noted subsequently. 
Subjects will be required to report spontaneously any AEs as well as the time of onset, end
time, and intensity of these events. In addition, each subject will be regularly assessed by the 
medical staff throughout the clinical trial and whenever the investigator deems necessary. As 
a minimum, subjects will be questioned for AEs (and concomitant therapies) at the time 
points indicated in the Flow Chart. Assessment will be made using non-specific questions 
such as ‘How do you feel?’. Specific questions will be asked wherever necessary in order to 
more precisely describe an AE.
A carefully written record of all AEs shall be kept by the investigator in charge of the trial. 
Records of AEs shall include data on the time of onset, end time, intensity of the event, and 
any treatment or action required for the event and its outcome.
The following must be collected and documented on the appropriate CRF(s) by the 
investigator:

From signing the informed consent onwards until an individual subject’s end of trial: 


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 40 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
o
All AEs (serious and non-serious) and all AESIs 
o
The only exception to this rule are AEs (serious and non-serious) and AESIs 
in Phase I trials in healthy volunteers, when subjects discontinue from the trial 
due to screening failures prior to administration of any trial medication. In 
these cases, the subjects’ data must be collected at trial site but will not be 
entered in the CRF or trial database and will not be reported in the CTR.

After the individual subject’s end of trial: 
o
The investigator does not need to actively monitor the subject for AEs but 
should only report any occurrence of cancer and related SAEs and related 
AESIs of which the investigator may become aware of by any means of 
communication, e.g. phone call. Those AEs should, however, not be reported 
in the CRF.
AE reporting to the sponsor and timelines
5.2.6.2.2
The Investigator must report SAEs, AESIs, and non-serious AEs which are relevant for the 
reported SAE or AESI, on the BI SAE form via fax immediately (within 24 hours) to the 
sponsor’s unique entry point (country specific contact details will be provided in the ISF). 
The same timeline applies if follow-up information becomes available. In specific occasions,
the Investigator could inform the sponsor upfront via telephone. This does not replace the 
requirement to complete and fax the BI SAE form. 
With receipt of any further information to these events, a follow-up SAE form has to be 
provided. For follow-up information, the same rules and timeline apply as for initial 
information.
Information required
5.2.6.2.3
All (S)AEs, including those persisting after the individual subject’s end of trial, must be 
followed up until they have resolved, have been sufficiently assessed as ‘chronic’ or ‘stable’, 
or no further information can be obtained.
Pregnancy
5.2.6.2.4
Once the male subject has been enrolled in the clinical trial and has taken trial medication, 
and if a partner of the male trial participant becomes pregnant, the investigator must report 
any drug exposure during pregnancy in a partner of the male trial participant immediately 
(within 24 hours) by means of Part A of the Pregnancy Monitoring Form to the sponsor’s 
unique entry point, after a written consent of the pregnant partner.
The outcome of the pregnancy associated with the drug exposure during pregnancy must be 
followed up and reported to the sponsor’s unique entry point on the Pregnancy Monitoring 
Form for Clinical Trials (Part B).
The ISF will contain the Pregnancy Monitoring Form for Clinical Trials (Part A and Part B) 
as well as non-trial specific information and consent for the pregnant partner.
As pregnancy itself is not to be reported as an AE, in the absence of an accompanying SAE 
and/or AESI, only the Pregnancy Monitoring Form for Clinical Trials and not the SAE form 


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 41 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
is to be completed. If there is an SAE and/or AESI associated with the pregnancy, an SAE 
form must be completed in addition.
5.3
DRUG CONCENTRATION MEASUREMENTS AND 
PHARMACOKINETICS
5.3.1
Assessment of pharmacokinetics
For the assessment of pharmacokinetics, blood samples will be collected at the time points 
indicated in the Flow Chart. The actual sampling times will be recorded and used for 
determination of pharmacokinetic parameters. 
5.3.2
Methods of sample collection
5.3.2.1
Blood sampling for pharmacokinetic analysis of BI 1323495
For quantification of BI 1323495 concentrations in plasma, 2.7 mL of blood will be drawn
from an antecubital or forearm vein into a K2-EDTA (dipotassium ethylenediaminetetraacetic
acid)-anticoagulant blood drawing tube at the times indicated in the Flow Chart. Blood will 
be withdrawn by means of either an indwelling venous catheter or by venepuncture with a 
metal needle.
At a minimum, the sample tube labels should list BI trial number, subject number, visit, 
planned sampling time, and the analyte (BI 1323495). 
5.3.2.2
Blood sampling for pharmacokinetic analysis of itraconazole
For quantification of itraconazole concentrations in plasma, 2.7 mL of blood will be drawn 
from an antecubital or forearm vein into a K2-EDTA anticoagulant blood drawing tube at the 
times indicated in the Flow Chart. Blood will be withdrawn by means of either an indwelling 
venous catheter or by venepuncture with a metal needle.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 42 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
At a minimum, the sample tube labels should list BI trial number, subject number, visit, 
planned sampling time, and the analyte ‘Itra’.
5.3.3
Analytical determinations
5.3.3.1
Analytical determination of analyte plasma concentration
BI 1323495 as well as itraconazole concentrations in plasma will be determined by validated 
LC-MS/MS (liquid chromatography tandem mass spectrometry) assays. All details of the 
analytical method will be available prior to the start of sample analysis.
5.3.3.2
Further use of plasma samples
After completion of the quantification of BI 1323495 and itraconazole in plasma, the left-
over and/or back-up aliquots may be used for further methodological investigations, e.g. for 
stability testing or assessments of metabolites (including, if applicable, re-analysis of parent 
compound). However, only data related to the analyte and/or its metabolite(s) including anti-
drug antibodies (if applicable) will be generated by these additional investigations. The study 
samples will be discarded after completion of the additional investigations but not later than 5 
years after the CTR is archived.
The results of any further investigations are not planned to be part of the CTR but can be 
included into the CTR if necessary.
5.4
BIOBANKING
Not applicable.
5.5
OTHER ASSESSMENTS


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 43 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
5.6
APPROPRIATENESS OF MEASUREMENTS
All measurements performed during this trial are standard measurements and will be 
performed in order to monitor subjects’ safety and to determine pharmacokinetic parameters 
in an appropriate way. The scheduled measurements will allow monitoring of changes in vital 
signs, standard laboratory values, and ECG parameters that might occur as a result of 
administration of trial medication. The safety assessments are standard, are accepted for 
evaluation of safety and tolerability of an orally administered drug, and are widely used in 
clinical trials. The pharmacokinetic parameters and measurements outlined in Section 5.4 are 
generally used assessments of drug exposure. 


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 44 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
6.
INVESTIGATIONAL PLAN
6.1
VISIT SCHEDULE
Exact times of measurements outside the permitted time windows will be documented. The 
acceptable time windows for screening, the end of trial examination, and measurements and 
assessments scheduled to occur ‘before’ trial medication administrations are provided in the 
Flow Chart.
If not stated otherwise in the Flow Chart, the acceptable deviation from the scheduled time 
for the assessment of safety (e.g. vital signs, ECG, laboratory tests) will be ± 30 min.
If scheduled in the Flow Chart at the same time as a meal, blood sampling, vital signs, and 
12-lead ECG recordings have to be done first. Furthermore, if several measurements 
including venepuncture are scheduled for the same time, venepuncture should be the last of 
the measurements due to its inconvenience to the subject and possible influence on 
physiological parameters.
For planned blood sampling times, refer to the Flow Chart. While these nominal times should 
be adhered to as closely as possible, the actual sampling times will be recorded and used for 
the determination of pharmacokinetic parameters.
If a subject misses an appointment, it will be rescheduled if possible. The relevance of 
measurements outside the permitted time windows will be assessed no later than at the Report 
Planning Meeting.
6.2
DETAILS OF TRIAL PROCEDURES AT SELECTED VISITS
6.2.1
Screening period
After having been informed about the trial, all subjects will provide written informed consent 
in accordance with GCP and local legislation prior to enrolment in the study.
For information regarding laboratory tests (including drug and virus screening), ECG, vital 
signs, and physical examination, refer to Sections 5.2.3 to 5.2.5.
6.2.2
Treatment periods
Each subject is expected to participate in 2 treatment periods (Days -3 to -1, 1, 2, 3, 4, and 5 
in Period 1 and Days -3, -2, -1, 1, 2, 3, 4, 5, 6, 7 , and 8 in Period 2). At least 7 days will 
separate BI 1323495 drug administrations in the first and second treatment period.
On Day 1 of each treatment period, study participants will be admitted to the trial site. They 
will be kept under close medical surveillance for at least 24 h (period 1) and 34 h (period 2) 
following administration of BI 1323495, respectively. The subjects will then be allowed to 
leave the trial site after formal assessment and confirmation of their fitness. On all other study 
days, subjects will be treated in an ambulatory fashion.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 45 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
For details on time points and procedures for collection of plasma samples for PK analysis, 
refer to Flow Chart and Section 5.3.2.
The safety measurements performed during the treatment period are specified in Section 5.3
of this protocol and in the Flow Chart. For details on times of all other trial procedures, refer 
to the Flow Chart. AEs and concomitant therapy will be assessed continuously from 
screening until the end of trial examination.
6.2.3
Follow-up period and trial completion
For AE assessment, laboratory tests, recording of ECG and vital signs, and physical 
examination during the follow-up period, see Sections 5.2.2 to 5.2.6.
Subjects who discontinue treatment before the end of the planned treatment period should 
undergo the EoTrial Visit.
All abnormal values (including laboratory parameters) that are assessed as clinically relevant 
by the investigator will be monitored using the appropriate tests until a return to a medically 
acceptable level is achieved. (S)AEs persisting after a subject’s EoTrial Visit must be 
followed until they have resolved, have been sufficiently characterised, or no further 
information can be obtained. 


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 46 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
7.
STATISTICAL METHODS AND DETERMINATION OF
SAMPLE SIZE
7.1
STATISTICAL DESIGN – MODEL
The main objective of this trial is to investigate the relative bioavailability of BI 1323495 in 
plasma when given as oral single dose 
 together with multiple doses of itraconazole 
(Test, T) as compared to when given alone as oral single dose (Reference, R) on the basis of 
the primary and secondary pharmacokinetic endpoints, as listed in Sections 2.1.2 and 2.1.3. 
The trial will be conducted as a two-treatment, two-period, fixed-sequence design, which 
allows intra-subject comparisons. It will be evaluated statistically by use of a linear model for 
logarithmically transformed PK endpoints.
The assessment of safety and tolerability is a further objective of this trial, and will be 
evaluated by descriptive statistics for the parameters specified in Section 2.2.2.2.
7.2
NULL AND ALTERNATIVE HYPOTHESES
The relative bioavailability of BI 1323495 in plasma when given with multiple oral doses of 
itraconazole (T) versus single oral dose of BI 1323495 alone (R) will be estimated by the
ratios of the geometric means (T/R), and their corresponding 2-sided 90% confidence 
intervals (CIs) will be provided. This method corresponds to the two one-sided t-test 
procedure, each at the 5% significance level. Since the main focus is on estimation and not 
testing, a formal hypothesis test and associated acceptance range is not specified.
7.3
PLANNED ANALYSES
Analysis sets
Statistical analyses will be based on the following analysis sets:

Treated set (TS): The treated set includes all subjects who were entered and treated 
with at least one dose of study drugs. The treated set will be used for safety analyses.
Pharmacokinetic analysis set (PKS): This set includes all subjects in the treated set 
(TS) who provide at least one PK endpoint that was defined as primary or secondary
and was not excluded due to a protocol deviation relevant to the evaluation of PK or 
due to PK non-evaluability (as specified in the following subsection 
‘Pharmacokinetics’). Thus, a subject will be included in the PKS, even if he 
contributes only one PK parameter value for one period to the statistical assessment.
Descriptive and model based analyses of PK parameters will be based on the PKS.
Adherence to the protocol will be assessed by the trial team. Important protocol deviation
(IPD) categories will be suggested in the IQRM plan, IPDs will be identified no later than in 
the Report Planning Meeting, and the IPD categories will be updated as needed.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 47 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Pharmacokinetics
The pharmacokinetic parameters listed in Sections 2.1 and 2.2 for BI 1323495 will be 
calculated according to the relevant SOP of the Sponsor (001-MCS-36-472). 
Plasma concentration data and parameters of a subject will be included in the statistical 
pharmacokinetic (PK) analyses if they are not flagged for exclusion due to a protocol 
deviation relevant to the evaluation of PK (to be decided no later than in the Report Planning 
Meeting) or due to PK non-evaluability (as revealed during data analysis, based on the 
criteria specified below). Exclusion of a subject’s data will be documented in the CTR.
Relevant protocol deviations may be

Incorrect trial medication taken, i.e. the subject received at least one dose of trial
medication the subject was not assigned to

Incorrect dose of trial medication taken

Use of restricted medications
Plasma concentrations and/or parameters of a subject will be considered as non-evaluable, if 
for example

The subject experienced emesis that occurred at or before two times median tmax of 
the respective treatment (Median tmax is to be determined excluding the subjects 
experiencing emesis

A predose concentration of BI 1323495 is >5% Cmax value of that subject in the 
respective treatment period

Missing samples/concentration data at important phases of PK disposition curve
Plasma concentration data and parameters of a subject which is flagged for exclusion will be 
reported with its individual values but will not be included in the statistical analyses. 
Descriptive and inferential statistics of PK parameters will be based on the PKS.
Only concentration values within the validated concentration range and actual sampling times 
will be used for the calculation of pharmacokinetic parameters. Concentrations used in the 
pharmacokinetic calculations will be in the same format provided in the bioanalytical report, 
(that is, to the same number of decimal places provided in the bioanalytical report). 
7.3.1
Primary endpoint analyses
Primary analyses
The statistical model used for the analysis of the primary endpoints will be an analysis of 
variance (ANOVA) model on the logarithmic scale. That is, the PK endpoints will be log-
transformed (natural logarithm) prior to fitting the ANOVA model. This model will include 
effects accounting for the following sources of variation: subject and treatment. The effect 
'subject' will be considered as random, whereas the effect ‘treatment’ will be considered as 
fixed. The model is described by the following equation:


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 48 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
ykm = + sm + k + ekm, where
ykm = logarithm of response measured on subject m receiving treatment k,
= the overall mean,
sm = the effect associated with the mth subject, m = 1, 2, ..., n,
k = the kth treatment effect, k = 1, 2,
ekm = the random error associated with the mth subject who received treatment k.
where s ~ N(0, σ
) i.i.d., e ~ N(0, σ
 ) i.i.d. and sm, ekm are independent random 
variables. The indices ‘B’ and ‘W’ correspond to ‘between’ and ‘within’ variability, 
respectively.
Point estimates for the ratios of the geometric means (test/reference) for the primary 
endpoints (see Section 2.1) and their two-sided 90% confidence intervals (CIs) will be 
provided.
For each endpoint, the difference between the expected means for log(T)-log(R) will be 
estimated by the difference in the corresponding adjusted means (Least Squares Means).
Additionally their two-sided 90% confidence intervals will be calculated based on the 
residual error from the ANOVA and quantiles from the t-distribution. These quantities will 
then be back-transformed to the original scale to provide the point estimate and 90% CIs for 
each endpoint.
7.3.2
Secondary endpoint analyses
The secondary endpoints (refer to Section 2.1.3) will be calculated according to the BI SOP 
‘Standards and processes for analyses performed within Clinical Pharmacokinetics/ 
Pharmacodynamics’ (001-MCS-36-472) and will be assessed statistically using the same 
methods as described for the primary endpoints.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 49 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
7.3.4
Safety analyses
Safety will be analysed based on the assessments described in Section 2.2.2.2. All treated 
subjects (TS, refer to Section 7.2) will be included in the safety analysis. Safety analyses will 
be descriptive in nature and based on BI standards. No hypothesis testing is planned.
For all analyses, the treatment actually administered (= treatment at onset) to the subject will 
be used (any deviations will be discussed in the Report Planning Meeting).
Treatments will be compared in a descriptive way. Tabulations of frequencies/proportions 
will be used to evaluate categorical (qualitative) data, and tabulations of descriptive statistics 
will be used to analyse continuous (quantitative) data.
Measurements (such as ECG, vital signs, or laboratory parameters) or AEs will be assigned to 
treatments (see Section 4.1) based on the actual treatment at the planned time of the 
measurement or on the recorded time of AE onset (concept of treatment emergent AEs).
Therefore, measurements planned or AEs recorded prior to first intake of trial medication will 
be assigned to the screening period, those between first trial medication intake and end of 
REP (see Section 1.2.3) will be assigned to the treatment period. Events occurring after the 
REP but prior to next intake or end of trial termination date will be assigned to ’follow-up’. 
In case of two or more treatments, the follow-up will be summarized according to the 
previous treatment. These assignments including the corresponding time intervals will be 
defined in detail in the TSAP. Note that AEs occurring after the last per protocol contact but 
entered before final database lock will be reported to Pharmacovigilance only and will not be 
captured in the trial database.
Additionally, further treatment intervals (analysing treatments) may be defined in the TSAP 
in order to provide summary statistics for time intervals, such as combined treatments, on-
treatment totals, or periods without treatment effects (such as screening and follow-up 
intervals).
Adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). Frequency, severity, and causal relationship of AEs will be tabulated by 
treatment, system organ class, and preferred term. SAEs, AESIs (see Section 5.2.6.1), and 
other significant AEs (according to ICH E3) will be listed separately.
Previous and concomitant therapies will be presented per treatment group without 
consideration of time intervals and treatment periods.
Laboratory data will be compared to their reference ranges. Values outside the reference 
range as well as values defined as possibly clinically significant will be highlighted in the 
listings. Additionally, differences from baseline will be evaluated.
Vital signs or other safety-relevant data will be assessed with regard to possible on-treatment 
changes from baseline.
Relevant ECG findings will be reported as AEs.
7.4
INTERIM ANALYSES
No interim analysis is planned.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 50 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
7.5
HANDLING OF MISSING DATA
7.5.1
Safety
It is not planned to impute missing values for safety parameters.
7.5.2
Pharmacokinetics
Handling of missing PK data will be performed according to the relevant Corporate 
Procedure (001-MCS-36-472).
PK parameters that cannot be reasonably calculated based on the available drug 
concentration-time data will not be imputed.
7.6
RANDOMISATION
Randomisation is not applicable in this open-label, single arm study. All subjects will receive 
the same treatments in the same order
7.7
DETERMINATION OF SAMPLE SIZE
It is planned to enter a total of 14 subjects in the trial, accounting for up to 2 dropouts or non 
PK evaluable subjects. The planned sample size is not based on a power calculation but is 
considered sufficient to achieve the aims of this exploratory trial. 
With this sample size, the following precision in estimating the ratio of geometric means 
(T/R) can be expected with 95% tolerance probability. Precision is defined as the ratio of 
upper CI limit to the relative BA estimate. Note that the precision is independent of the actual 
ratio of geometric means.
The observed coefficient of variation (gCV%) after a single oral dose of BI 1323495
 
in trial 1405-0001 was roughly 66.3% for Cmax and 104% for AUC. The reported variability 
originated from a parallel group estimates total variability. However, for this trial as a 
crossover trial intra-individual gCV is needed. Assuming the correlation between two 
responses of the same subjects ρ=0.5 for Cmax and ρ=0.75 for AUC, we can estimate the intra-
individual variability out of the total variability. The calculated values would be roughly 
44.7% for Cmax and 44.9% for AUC. 
For various assumptions for the gCV, Table 7.7: 1 provides an overview of the achievable 
precision for estimating the ratio of geometric means (test/reference). For illustrative 
purposes, the expected 90% confidence intervals are displayed for different values of the 
ratios T/R of geometric means.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 51 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Table 7.7: 1
Precision that can be expected with 95% probability and illustrative 
two-sided 90% confidence intervals around the ratios of geometric 
means (T/R) for different gCVs in a one-way crossover trial (N=12)
gCV [%]
Precision upper 
CL / relative BA 
estimate
Ratio [%]*
Lower CL [%]
Upper CL [%]
30.0
1.334
100
74.99
133.36
30.0
1.334
150
112.48
200.03
30.0
1.334
200
149.98
266.71
40.0
1.459
100
68.54
145.90
40.0
1.459
150
102.81
218.85
40.0
1.459
200
137.08
291.80
50.0
1.589
100
62.93
158.91
50.0
1.589
150
94.39
238.37
50.0
1.589
200
125.85
317.83
*Ratio of geometric means (test/reference) for a PK endpoint is defined by exp(T)/exp(R).
The expected 90% confidence interval limits in the table were derived by
CI limit, = exp(ln(θ) ± ω),
with θ being the ratio (T/R) on original scale and ω the distance from the estimate θ to either 
confidence interval limit on the log-scale, which was obtained from the achievable precision 
on the original scale.
The calculation was performed as described by Julious (R11-5230) using R Version 3.4.2.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 52 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
8.
INFORMED CONSENT, TRIAL RECORDS, DATA 
PROTECTION, PUBLICATION POLICY, AND 
ADMINISTRATIVE STRUCTURE
The trial will be carried out in compliance with the protocol, the ethical principles laid down 
in the Declaration of Helsinki, in accordance with the ICH Harmonized Guideline for Good 
Clinical Practice (GCP), relevant BI Standard Operating Procedures (SOPs), the EU 
regulation 536/2014, and other relevant regulations. Investigators and site staff must adhere 
to these principles.
Standard medical care (prophylactic, diagnostic, and therapeutic procedures) remains the 
responsibility of the subject’s treating physician.
The investigator will inform the sponsor immediately of any urgent safety measures taken to 
protect the trial subjects against any immediate hazard, as well as of any serious breaches of 
the protocol or of ICH GCP.
The Boehringer Ingelheim transparency and publication policy can be found on the following 
web page: trials.boehringer-ingelheim.com. As a general rule, no trial results should be 
published prior to archiving of the CTR.
The terms and conditions of the insurance coverage are made available to the investigator and 
the subjects, and are stored in the ISF.
8.1
TRIAL APPROVAL, SUBJECT INFORMATION, INFORMED CONSENT
This trial will be initiated only after all required legal documentation has been reviewed and 
approved by the respective Institutional Review Board (IRB) / Independent Ethics Committee 
(IEC) and competent authority (CA) according to national and international regulations. The 
same applies for the implementation of changes introduced by amendments.
Prior to a subject’s participation in the trial, written informed consent must be obtained from 
each subject (or the subject’s legally accepted representative) according to ICH-GCP and to 
the regulatory and legal requirements of the participating country. Each signature must be 
personally dated by each signatory and the informed consent and any additional subject-
information form retained by the investigator as part of the trial records. A signed copy of the 
informed consent and any additional subject information must be given to each subject or the 
subject’s legally accepted representative.
The subject must be given sufficient time to consider participation in the trial. The 
investigator or delegate obtains written consent of the subject’s own free will with the 
informed consent form after confirming that the subject understands the contents. The 
investigator or 
 delegate must sign (or place a seal on) and date the informed consent form. 
If a trial collaborator has given a supplementary explanation, the trial collaborator also signs 
(or places a seal on) and dates the informed consent.
Re-consenting may become necessary when new relevant information becomes available and 
should be conducted according to the sponsor’s instructions.
The consent and re-consenting process should be properly documented in the source 
documentation.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 53 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
8.2
DATA QUALITY ASSURANCE
A risk-based approach is used for trial quality management. It is initiated by the assessment 
of critical data and processes for trial subject protection and reliability of the results as well as 
identification and assessment of associated risks. An Integrated Quality and Risk 
Management Plan documents the rationale and strategies for risk management during trial 
conduct including monitoring approaches, vendor management and other processes focusing 
on areas of greatest risk. 
Continuous risk review and assessment may lead to adjustments in trial conduct, trial design 
or monitoring approaches. 
A quality assurance audit/inspection of this trial may be conducted by the sponsor, sponsor’s 
designees, or by IRB / IEC or by regulatory authorities. The quality assurance auditor will 
have access to all medical records, the investigator’s trial-related files and correspondence, 
and the informed consent documentation of this clinical trial.
8.3
RECORDS
CRFs for individual subjects will be provided by the sponsor. drug accountability, refer to 
Section 4.1.8.
ClinBaseTM
In the Human Pharmacology Centre (HPC) – Boehringer Ingelheim's Phase I unit – the 
validated ClinBaseTM system is used for processing information and controlling data 
collected in clinical studies. In addition to its function as a procedure control system, 
ClinBaseTM serves as data base. Instead of being entered into CRFs, selected data are directly 
entered into the system.
8.3.1
Source documents
In accordance with regulatory requirements, the investigator should prepare and maintain 
adequate and accurate source documents and trial records for each trial subject that include 
all observations and other data pertinent to the investigation. Source data as well as reported 
data should follow the ‘ALCOA principles’ and be attributable, legible, contemporaneous, 
original, and accurate. Changes to the data should be traceable (audit trail).
Data reported on the CRF must be consistent with the source data or the discrepancies must 
be explained.
Before providing any copy of subjects’ source documents to the sponsor, the investigator 
must ensure that all subject identifiers (e.g., subject’s name, initials, address, phone number, 
and social security number) have properly been removed or redacted to ensure subject 
confidentiality.
If the subject is not compliant with the protocol, any corrective action (e.g. re-training) must 
be documented in the subject file.
For the CRF, data must be derived from source documents, for example:


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 54 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018

Subject identification: sex, year of birth (in accordance with local laws and 
regulations)

Subject participation in the trial (substance, trial number, subject number, date subject 
was informed)

Dates of subject’s visits, including dispensing of trial medication

Medical history (including trial indication and concomitant diseases, if applicable)

Medication history

AEs and outcome events (onset date [mandatory], and end date [if available])

SAEs (onset date [mandatory], and end date [if available])

Concomitant therapy (start date, changes)

Originals or copies of laboratory results and other imaging or testing results, with 
proper documented medical evaluation (in validated electronic format, if available)

ECG results (original or copies of printouts)

Completion of subject’s participation in the trial (end date; in case of premature 
discontinuation, document the reason for it, if known)

Prior to allocation of a subject to a treatment into a clinical trial, there must be 
documented evidence in the source data (e.g. medical records) that the trial participant 
meets all inclusion criteria and does not meet any exclusion criteria. The absence of 
records (either medical records, verbal documented feedback of the subject or testing 
conducted specific for a protocol) to support inclusion/exclusion criteria does not 
make the subject eligible for the clinical trial.
Data directly entered into ClinBaseTM (that is, without prior written or electronic record) are 
considered to be source data. The place where data are entered first will be defined in a trial 
specific Source Data Agreement. The data in ClinBaseTM are available for inspection at any 
time.
8.3.2
Direct access to source data and documents
The investigator /institution will allow site trial-related monitoring, audits, IRB / IEC review 
and regulatory inspections. Direct access must be provided to the CRF and all source 
documents/data, including progress notes, copies of laboratory and medical test results, which 
must be available at all times for review by the Clinical Research Associate, auditor and 
regulatory inspector (e.g. FDA). They may review all CRFs and informed consents. The 
accuracy of the data will be verified by direct comparison with the source documents 
described in Section 8.3.1. The sponsor will also monitor compliance with the protocol and 
GCP.
8.3.3
Storage period of records
Trial site:
The trial site(s) must retain the source and essential documents (including ISF) according to 
the local requirements valid at the time of the end of the trial.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 55 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Sponsor:
The sponsor must retain the essential documents according to the sponsor’s SOPs.
8.4
EXPEDITED REPORTING OF ADVERSE EVENTS
BI is responsible to fulfil their legal and regulatory reporting obligation in accordance with 
regulatory requirements.
8.5
STATEMENT OF CONFIDENTIALITY AND SUBJECT PRIVACY
Individual subject data obtained as a result of this trial is considered confidential and 
disclosure to third parties is prohibited with the exceptions noted in Section 8.7. 
Data protection and data security measures are implemented for the collection, storage and 
processing of patient data in accordance with the principles 6 and 12 of the WHO GCP 
handbook.
Personalised treatment data may be given to the subject’s personal physician or to other 
appropriate medical personnel responsible for the subject’s welfare. Data generated at the site 
as a result of the trial need to be available for inspection on request by the participating 
physicians, the sponsor’s representatives, by the IRB / IEC and the regulatory authorities.
8.5.1
Collection, storage and future use of biological samples and corresponding 
data
Measures are in place to comply with the applicable rules for the collection, storage and 
future use of biological samples and clinical data, in particular

Sample and data usage has to be in accordance with the informed consent

The BI-internal facilities storing biological samples from clinical trial participants as 
well as the external storage facility are qualified for the storage of biological samples 
collected in clinical trials.

An appropriate sample and data management system, incl. audit trail for clinical data 
and samples to identify and destroy such samples according to ICF is in place

A fit for the purpose documentation (biomarker proposal, analysis plan and report) 
ensures compliant usage

A fit for purpose approach will be used for assay/equipment validation depending on 
the intended use of the biomarker data
Samples and/or data may be transferred to third parties and other countries as specified in the 
ICF.
8.6
TRIAL MILESTONES
The start of the trial is defined as the date of the enrolment of the first subject in the trial.
The end of the trial is defined as the ‘date of the last visit of the last subject in whole trial’ 
(‘Last Subject Completed’) or ‘end date of the last open AE’ or ‘date of the last follow-up 
test’ or ‘date of an AE has been decided as sufficiently followed-up’, whichever is latest.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 56 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Early termination of the trial is defined as the premature termination of the trial for any 
reason before the end of the trial as specified in this protocol.
Temporary halt of the trial is defined as any unplanned interruption of the trial by the 
sponsor with the intention to resume it.
Suspension of the trial is defined as an interruption of the trial based on a Health Authority 
request.
The EC/competent authority in each participating EU member state will be notified about the 
trial milestones according to the laws of each member state. 
A final report of the clinical trial data will be written only after all subjects have completed 
the trial in all countries (EU or non-EU), so that all data can be incorporated and considered 
in the report.
The sponsor will submit to the EU database a summary of the final trial results within one 
year from the end of a clinical trial as a whole, regardless of the country of the last patient 
(EU or non-EU).
8.7
ADMINISTRATIVE STRUCTURE OF THE TRIAL
The trial is sponsored by Boehringer Ingelheim (BI).
The trial will be conducted at the 
 
, under the supervision of the Principal Investigator. Relevant 
documentation on the participating (Principal) Investigators (e.g. their curricula vitae) will be 
filed in the ISF.
BI has appointed a Clinical Trial Leader, responsible for coordinating all required trial 
activities, in order to 

Manage the trial in accordance with applicable regulations and internal SOPs

Direct the clinical trial team in the preparation, conduct, and reporting of the trial

ensure appropriate training and information of Clinical Trial Managers, Clinical 
Research Associates, and investigators of participating trial sites
The trial medication will be provided by the Clinical Trial Supplies Unit, BI Pharma GmbH 
& Co. KG, Biberach, Germany (BI 1323495) or will be obtained by the clinical trial site from 
public pharmacy (itraconazole).
Safety laboratory tests will be performed by the local laboratory of the trial site 
 
Analyses of BI 1323495 concentrations in plasma will be performed at the Department of 
Drug Metabolism and Pharmacokinetics Germany, BI Pharma GmbH & Co. KG, Biberach, 
Germany.
Analyses of itraconazole concentrations in plasma will be performed at 
On-site monitoring will be performed by BI or a contract research organisation appointed by 
BI.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 57 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Data management and statistical evaluation will be done by BI or a contract research 
organisation appointed by BI according to BI SOPs.
Tasks and functions assigned in order to organise, manage, and evaluate the trial are defined 
according to BI SOPs. A list of responsible persons and relevant local information can be 
found in the ISF.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 58 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
9.
REFERENCES 
9.1
PUBLISHED REFERENCES
P07-13746
Heeswijk RPG van, Bourbeau M, Campbell P, Seguin I, Chauhan BM, 
Foster BC, Cameron DW. Time-dependent interaction between 
lopinavir/ritonavir and fexofenadine. J Clin Pharmacol 46, 758-767 
(2006).
P15-06298
Ministry of Health, Labour and Welfare. Drug interaction guideline for 
drug development and labeling recommendations (draft). 
http://www.solvobiotech.com/documents/Japanese_DDI_guideline_(draft)
_2014Jan.pdf (access date: 22 June 2015); Ministry of Health, Labour and 
Welfare; 2014.
P15-06991
European Medicines Agency (EMA). Committee for Human Medicinal
Products (CHMP): guideline on the investigation of drug interactions (21 
June 2012, CPMP/EWP/560/95/rev. 1 corr. 2). 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guid
eline/2012/0 7/WC500129606.pdf (access date: 8 July 2015); London: 
European Medicines Agency (EMA); 2012.
P17-01597
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global 
strategy for the diagnosis, management, and prevention of chronic 
obstructive lung disease (2017 report). http://goldcopd.org/gold-2017-
global-strategy-diagnosis-management-prevention-co pd/ (accessd date: 9 
February 2017); Global Initiative for Chronic Obstructive Lung Disease 
(GOLD); 2017.
R01-0516
Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in 
patients receiving the systemic antimycotics ketoconazole or itraconazole.
Clin Pharmacol Ther 1994. 55(5):481-485. 
R08-1652
Kharasch ED, Bedynek PS, Walker A, Whittington D, Hoffer C. 
Mechanism of ritonavir changes in methadone pharmacokinetics and 
pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein 
activities. Clinical Pharmacology and Therapeutics, advance online 
publication 9 July 2008, doi:10.1038/clpt.2008.102 Clin Pharmacol Ther 
2008.
R10-1102
Templeton IE, Thummel KE, Kharasch ED, Kunze KL, Hoffer C, Nelson 
WL, Isoherranen N. Contribution of itraconazole metabolites to inhibition 
of CYP3A4 in vivo. Clin Pharmacol Ther 2008; 83(1):77-85. Clin 
Pharmacol Ther 1994. 55(5):481-485.
R11-5230
Julious SA. Sample sizes for clinical trials. Boca Raton: Taylor & Francis
Group; 2010.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 59 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
R12-1392
Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, 
Kusek JW, Eggers P, Lente F van, Greene T, Coresh J, Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI). A new equation to 
estimate glomerular filtration rate. Ann Intern Med 2009; 150(9):604-612.
R15-3252
Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal 
clearance of digoxin. Ther Drug Monit 1997. 19(6):609-613.
R17-3742
Barone JA, Moskovitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman 
RH, et al. Food interaction and steady-state pharmacokinetics of 
itraconazole oral solution in healthy volunteers. Pharmacotherapy 1998;
18(2):295-301.
R17-3743
Willems L, Geest R van der, Beule K de. Itraconazole oral solution and 
intravenous formulations: a review of pharmacokinetics and 
pharmacodynamics. J Clin Pharm Ther 2001; 26:159-169.
R17-3744
Liu L, Bello A, Dresser MJ, Heald D, Komjathy SF, O'Mara E, et al. Best 
practices for the use of itraconazole as a replacement for ketoconazole in 
drug-drug interaction studies. J Clin Pharmacol 2016. 56(2):143-151.
R18-0241
Guidance for industry: clinical drug interaction studies - study design, data
analysis, and clinical implications (draft guidance, this guidance document 
is being distributed for comment purposes only) (October 2017, clinical 
pharmacology). 
https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf (access 
date: 19 January 2018); Silver Spring: U.S. Department of Health and 
Human Services, Food and Drug Administration, Center for Drug 
Evaluation and Research (CDER) 2017.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 60 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
R18-2643
Sporanox 10 mg/ml oral solution (Janssen-Cilag) (summary of product 
characteristics, updated 01-Mar-2018). https://www.medicines.org.uk/
emc/product/1522/smpc/print (access date: 14 August 2018); 2018.
R18-2644
Sempera Liquid 10 mg/ml, Loesung zum Einnehmen (Janssen-Cilag) 
(Fachinformation, Stand der Information: Dezember 2017). 2017.
R94-1529 
Chow SC, Liu JP, editors. Design and analysis of bioavailability and
bioequivalence studies. New York: Marcel Dekker Inc., 1992.
9.2
UNPUBLISHED REFERENCES
001-MCS-36-472 Standards and processes for analyses performed within Clinical 
Pharmacokinetics/Pharmacodynamics. Current version.
c02336088
Relative bioavailability of a single oral dose of BI 691751 when 
administered alone or in combination with multiple oral doses of 
itraconazole in healthy male subjects (an open-label, randomised, 
twoperiod, two-sequence crossover study). 1334.10. 09 Jan 2015.
c03355329
 Relative bioavailability of a single oral 
dose of BI 425809 when administered alone or in combination with 
multiple oral doses of itraconazole in healthy male subjects (an open-
label, two-period, fixed-sequence trial). 1346.10. 03 Dec 2015.
c08928447
, Effect of multiple doses of itraconazole 
on the pharmacokinetics of a single oral dose of BI 1026706 in healthy 
male subjects (an open-label, randomised, two-period, two-sequence 
crossover study). 1320.20. 29 Sep 2016.
c21238478
Investigator’s Brochure BI 1323495. COPD. 18 Mar 2019.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 61 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
10.
APPENDICES
Not applicable.


Boehringer Ingelheim
18 Jun 2019
BI Trial No.: 1405-0009
c26556329-02
Trial Protocol
Page 62 of 62
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
11.
DESCRIPTION OF GLOBAL AMENDMENT(S)
11.1
GLOBAL AMENDMENT 1
Date of amendment
18 June 2019
EudraCT number
EU number
2019-001570-28
BI Trial number
1405-0009
BI Investigational Medicinal 
Product(s)
BI 1323495
Title of protocol
Relative bioavailability of a single oral dose of BI 
1323495 when administered alone or in combination 
with multiple oral doses of itraconazole in healthy 
male subjects (an open-label, one-way crossover 
study)
To be implemented only after approval of the IRB / IEC / Competent 
Authorities
To be implemented immediately in order to eliminate hazard – IRB / IEC / 
Competent Authority to be notified of change with request for approval
Can be implemented without IRB / IEC / Competent Authority approval as 
changes involve logistical or administrative aspects only
Section to be changed
1.
2.
3.
4.
5.
6.
Flow Chart
1.4.2.5 Safety measures
3.3.3 Exclusion criteria
3.3.4.1 Discontinuation of trial treatment
3.3.4.3 Discontinuation of the trial by the sponsor
6.2.2 Treatment periods
Description of change
1.
2.
3.
4.
5.
6.
Inhouse stay in treatment period 2 extended to 34 h
Period of inhouse stay amended
Blood coagulation disorder in exclusion criterion no. 
5 added
Insertion of an additional criterion for 
discontinuation of an individual subject
Trial termination criterion no. 2 rephrased
Period of inhouse stay amended
Rationale for change
1.
2.
3.
4.
5.
6.
Health authority/EC request
Health authority/EC request
Health authority/EC request
Health authority/EC request
Health authority/EC request
Health authority/EC request


 
 
 
 
APPROVAL / SIGNATURE PAGE 
 
Document Number: 
 
Technical Version Number:
 
Document Name: 
 
 
 
                                                                                                                 
 
Title: 
 
 
 
 
                                                                                                                   
 
Signatures (obtained electronically) 
 
Meaning of Signature  
Signed by 
Date Signed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c26556329
2.0
clinical-trial-protocol-version-2
Relative bioavailability of a single oral dose of BI 1323495 when administered alone
or in combination with multiple oral doses of itraconazole in healthy male subjects
(an open-label, one-way crossover study)
Author-Clinical Trial Leader
18 Jun 2019 10:27 CEST
Approval-Team Member Medicine
18 Jun 2019 10:39 CEST
Author-Trial Statistician
18 Jun 2019 11:04 CEST
Approval-Therapeutic Area
18 Jun 2019 11:53 CEST
Verification-Paper Signature
Completion
19 Jun 2019 08:01 CEST
Author-Trial Clinical
Pharmacokineticist
26 Jun 2019 15:29 CEST


Boehringer Ingelheim 
Page 2 of 2
Document Number: 
 Technical Version Number:
 
 
 
(Continued) Signatures (obtained electronically) 
 
Meaning of Signature  
Signed by 
Date Signed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c26556329
2.0

SAP_001.pdf: 
TITLE PAGE
TRIAL STATISTICAL ANALYSIS PLAN
c29769550-01
BI Trial No.:
1405-0009
Title:
Relative bioavailability of a single oral dose of BI 1323495 when
administered alone or in combination with multiple oral doses of
itraconazole in healthy male subjects (an open-label, one-way
crossover study)
(including Protocol Amendment No.1 [c26556329-02])
Investigational
Product:
BI 1323495
Responsible trial 
statisticians:
Phone
Fax:
Date of statistical 
analysis plan:
21OCT2019 SIGNED
Version:
Final
Page 1 of 28
Proprietary confidential information
2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved.
This document may not - in full or in part - be passed on, reproduced, published or otherwise used without prior written permission.


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 2 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
1.
TABLE OF CONTENTS
TITLE PAGE ...........................................................................................................................1
1.
TABLE OF CONTENTS......................................................................................2
LIST OF TABLES...................................................................................................................4
2.
LIST OF ABBREVIATIONS ..............................................................................5
3.
INTRODUCTION.................................................................................................7
4.
CHANGES IN THE PLANNED ANALYSIS OF THE STUDY......................8
5.
ENDPOINTS .........................................................................................................9
5.1
PRIMARY ENDPOINTS.....................................................................................9
5.2
SECONDARY ENDPOINTS...............................................................................9
5.2.1
Key secondary endpoints......................................................................................9
5.2.2
Secondary endpoints.............................................................................................9
6.
GENERAL ANALYSIS DEFINITIONS .........................................................11
6.1
TREATMENTS...................................................................................................11
6.2
IMPORTANT PROTOCOL DEVIATIONS....................................................13
6.3
SUBJECT SETS ANALYSED...........................................................................15
6.5
POOLING OF CENTRES .................................................................................16
6.6
HANDLING OF MISSING DATA AND OUTLIERS....................................16
6.7
BASELINE, TIME WINDOWS AND CALCULATED VISITS ...................16
7.
PLANNED ANALYSIS......................................................................................18
7.1
DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS.........19
7.2
CONCOMITANT DISEASES AND MEDICATION .....................................20
7.3
TREATMENT COMPLIANCE........................................................................20
7.4
PRIMARY ENDPOINTS...................................................................................20
7.4.1
Primary analysis of the primary endpoints......................................................20
7.5
SECONDARY ENDPOINTS.............................................................................22
7.5.1
Key secondary endpoints....................................................................................22
7.5.2
Secondary endpoints...........................................................................................22
7.7
EXTENT OF EXPOSURE.................................................................................22
7.8
SAFETY ANALYSIS..........................................................................................23


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 3 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
7.8.1
Adverse Events ....................................................................................................23
7.8.2
Laboratory data ..................................................................................................25
7.8.3
Vital signs.............................................................................................................25
7.8.4
ECG......................................................................................................................25
7.8.5
Others...................................................................................................................25
8.
REFERENCES....................................................................................................26
10.
HISTORY TABLE..............................................................................................28


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 4 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
LIST OF TABLES
Table 6.1: 1
Treatments and labels used in the analysis.......................................................11
Table 6.2: 1
Handling of iPDs..............................................................................................14
Table 6.3: 1
Subject sets analysed........................................................................................16
Table 10: 1
History table .....................................................................................................28


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 5 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
2.
LIST OF ABBREVIATIONS
See Medicine Glossary:
website: glossary
Term
Definition / description
AESI
Adverse event of special interest
ALT
Alanine transaminase
ANOVA
Analysis of variance
AST
Aspartate transaminase
AUC0-tz
Area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 to the last quantifiable data point
AUC0-∞
Area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 extrapolated to infinity
BMI
Body mass index
BWU
Bioavailability/Bioequivalence, Within-Subject Design, uncontrolled w.r.t. 
time
CI
Confidence interval
Cmax
Maximum measured concentration of the analyte in plasma
CV
Arithmetic coefficient of variation
DBLM
Database lock meeting
DILI
Drug induced liver injury
gCV
Geometric coefficient of variation
gMean
Geometric mean
ITZ
Itraconazole
LLT
Lower level term
Max
Maximum
MedDRA
Medical Dictionary for Regulatory Activities
Min
Minimum
N
Number non-missing observations
P10
10th percentile
P90
90th percentile
PKS
PK parameter analysis set
Q1
1st quartile


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 6 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Term
Definition / description
Q3
3rd quartile
R / Ref
Reference treatment
RAGe
Report Appendix Generator system
SD
Standard deviation
SOC
System organ class
T
Test treatment
TS
Treated set
ULN
Upper limit of normal
WHO-DD
World Health Organization Drug Dictionary
XPKISTAT
Library of SAS® Macros for PK analysis


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 7 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
3.
INTRODUCTION
As per ICH E9 (1), the purpose of this document is to provide a more technical and detailed 
elaboration of the principal features of the analysis described in the protocol, and to include 
detailed procedures for executing the statistical analysis of the primary and secondary 
variables and other data.
This Trial statistical analysis plan (TSAP) assumes familiarity with the Clinical Trial Protocol 
(CTP), including protocol amendment. In particular, the TSAP is based on the planned 
analysis specification as written in CTP Section 7 “Statistical Methods and Determination of 
Sample Size”. Therefore, TSAP readers may consult the CTP for more background 
information on the study, e.g., on study objectives, study design and population, treatments, 
definition of measurements and variables, planning of sample size, randomisation.
Study data (including data entered in the RAVE EDC system and external data provided by 
suppliers) will be stored in a Clinical Data Repository (CDR).
Pharmacokinetic (PK) parameters will be calculated using Phoenix WinNonlinTM software 
(version 6.3 or higher, Certara USA Inc., Princeton, NJ, USA).
The statistical analyses will be performed within the validated working environment CARE, 
including SASTM (current Version 9.4, by SAS Institute Inc., Cary, NC, USA), and a number 
of SASTM-based tools (e.g., macros for the analyses of AE data or laboratory data; Report 
Appendix Generator system (RAGe) for compilation/formatting of the CTR appendices).


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 8 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
4.
CHANGES IN THE PLANNED ANALYSIS OF THE STUDY
All analyses as planned in the CTP will be performed and are described in more detail in this 
TSAP. The following change compared to the protocol will be made:
The PKS defined in the CTP will be called “Pharmacokinetic parameter analysis set” 
instead of “Pharmacokinetic analysis set”.


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 9 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
5.
ENDPOINTS
5.1
PRIMARY ENDPOINTS
Section 2.1.2 of the CTP: The following pharmacokinetic parameters will be determined for 
BI 1323495:

AUC0-tz (area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 to the last quantifiable data point)

Cmax (maximum measured concentration of the analyte in plasma)
The pharmacokinetic parameters listed in Sections 2.1 and 2.2 of the protocol for BI 1323495
will be calculated according to the BI Standard Operating Procedure (SOP) ‘Standards and 
processes for analyses performed within Clinical Pharmacokinetics/Pharmacodynamics’ 
[001-MCS-36-472] (7).
5.2
SECONDARY ENDPOINTS
5.2.1
Key secondary endpoints
This section is not applicable as no key secondary endpoints have been defined in the CTP.
5.2.2
Secondary endpoints
Section 2.1.3 of the CTP: The following pharmacokinetic parameter will be determined for 
BI 1323495:

AUC0-∞(area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 extrapolated to infinity)


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 10 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
5.3.2
Safety endpoints
Section 2.2.2.2 of the CTP: Safety and tolerability of the trial treatments will be assessed 
based on:

Adverse events (including clinically relevant findings from the physical examination)

Safety laboratory tests

12-lead ECG

Vital signs (blood pressure, pulse rate)


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 11 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
6.
GENERAL ANALYSIS DEFINITIONS
6.1
TREATMENTS
For basic study information on investigational products, assignment of treatment sequences 
and selection of doses, please see CTP, Sections 3 and 4.
The study will be performed as an open-label trial with two treatments (T and R) and one 
fixed sequence (R then T). There will be a washout period of at least 7 days between the 
administrations of BI 1323495 under Reference treatment and BI 1323495 under Test 
treatment.
In total, it was planned to assign 14 healthy male subjects.
For details of dosage and formulation see Table 6.1: 1 below:
Table 6.1: 1
Treatments and labels used in the analysis
Treatment
Short label
R
BI 1323495, 1*
 tablet, qd
BI 
T
BI 1323495, 1*
 tablet +Itraconazole 20ml, 10mg/ml, qd
BI + ITZ
Section 1.2.3 of the CTP: The Residual Effect Period (REP, i.e., the period after the last 
dose with measurable drug levels and/or pharmacodynamic effects still likely to be present) 
of BI 1323495 is approximately 7 days. […]
For the use of itraconazole in Treatment T, the REP is defined as 9 days after last 
administration of itraconazole on Day 7 in Period 2.
The following separate study phases will be defined for the analyses of AEs:


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 12 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies

Screening (ranging from 0:00 h on day of informed consent until first administration 
time of BI 1323495 alone in treatment period 1)

On treatment

BI alone (labelled “BI”, including REP; i.e. ranging from the time of first 
administration of BI 1323495 alone in treatment period 1 until 0:00 h on the 7th
day thereafter)

Itraconazole alone (labelled “ITZ”) (ranging from the time of first 
administration of Itraconazole until time of BI 1323495 administration in 
treatment period 2)

BI + ITZ (ranging from time of BI 1323495 administration in treatment period 2 
until 0:00 h on the 9th day after the last administration of Itraconazole OR until 
0:00h on the 7th day after the BI 1323495 administration in treatment period 2, 
whatever occurs later)

Follow-up (FU) (labelled “F/U BI”, “F/U BI+ITZ”, “F/U ITZ”)

F/U BI (ranging from the end of REP of BI 1323495 in treatment period 1 until 
the first administration of itraconazole in period 2 or until trial termination, 
whatever occurs first)

F/U BI+ITZ (ranging from the end of REP of BI 1323495 or itraconazole 
(whatever occurs later) in treatment period 2 until trial termination)

F/U ITZ (ranging from the end of REP of itraconazole in treatment period 2 until 
trial termination if subject discontinues treatment prior to BI 1323495 drug 
administration – if applicable)
Two types of AE displays will be provided in the report:
A) Section 15.3 and Appendix 16.1.13.1.8 (for ClinicalTrials.gov and EudraCT only) of the 
CTR displays:
In these displays, the on treatment phase will be analysed (labelled with the name of the 
study treatment (short label)). Screening and follow-up periods will not be included in 
this analysis. 
The following total will be provided in addition (Section 15.3 only):
a total over all on treatment phases involving BI ("BI Total on treatment")
a total over all on treatment phases included in this analysis ("Total on treatment")


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 13 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
B) Section 15.4 and Appendix 16.1.13.1.8 (except for ClinicalTrials.gov and EudraCT) of 
the CTR displays:
Screening 
On treatment (labelled with the name of the study treatment (short label))
Follow-up BI (labelled "FU BI")
Follow-up BI+ITZ (labelled "FU BI+ITZ")

Follow-up ITZ (labelled "F/U ITZ") – if applicable
In Section 16.1.13.1.8 AE tables, the following totals will be provided in addition:
a total over all on treatment phases involving BI ("BI Total")
a total over all study phases ("Total")
For detailed information on the handling of the treatments refer to Technical TSAP ADS plan 
and Analysis Data Reviewers guide. 
6.2
IMPORTANT PROTOCOL DEVIATIONS
Data discrepancies and deviations from the CTP will be identified for all treated subjects. 
Section 7.3 of the CTP: Adherence to the protocol will be assessed by the trial team. 
Important protocol deviation (IPD) categories will be suggested in the IQRM plan, IPDs will 
be identified no later than in the Report Planning Meeting, and the IPD categories will be 
updated as needed.
Consistency check listings (for identification of deviations of time windows) and a list of 
protocol deviations (e.g. deviations in drug administration, in blood sampling times, etc.) will 
be provided to be discussed at the report planning meeting (RPM). At this meeting, all 
manual deviations identified at the sites by the CRAs and deviations too complex to program 
will be reviewed by the trial team to decide which are considered important. For definition of 
important protocol deviations (iPD), and for the process of identification of these, refer to the 
Boehringer Ingelheim (BI) SOP "Identify and Manage Important Protocol Deviations (iPD)" 
(2).
If any iPDs are identified, they are to be summarised into categories and will be captured in 
an accompanying Excel spreadsheet (3). Categories which are considered to be iPDs in this 
trial are defined in the integrated quality and risk management plan (IQRMP). If the data 
show other iPDs, the definition in the IQRMP will be supplemented accordingly by the time 
of the Report Planning Meeting.
The iPDs will be summarised and listed. Table 6.2: 1 below specifies which kind of iPDs 
could potentially lead to exclusion from which analysis set. The decision on exclusion of 


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 14 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
patients from analysis sets will be made at the latest at the Report Planning Meeting, after 
discussion of exceptional cases and implications for analyses.
Table 6.2: 1
Handling of iPDs
iPD code
iPD Category & Brief Description
Excluded from which 
analysis set
iPD B1 
Informed consent not available/not done
All
iPD B2 
Informed consent too late
None
iPD A1
Inclusion Criteria Not Met
PKS
iPD A2
Exclusion Criteria Met
PKS
iPD C1
Incorrect trial medication taken
PKS
iPD C2
Randomisation not followed
PKS
iPD C3
Non-compliance
PKS
iPD C4
Medication code broken inappropriately
PKS
iPD C5
Incorrect intake of trial medication
PKS
iPD C6
Improper washout between treatments
PKS
iPD D1
Prohibited medication use
PKS
iPD D2
Mandatory medication not taken
PKS
iPD D3
Improper washout of concomitant medication
PKS
iPD E1
Certain violations of procedures used to 
measure primary or secondary data
PKS
iPD F1
Certain violations of time schedule used to 
measure primary or secondary data
PKS
iPD G1
Incorrect intake of meal
PKS
iPD G2
PDs affecting safety and rights of subjects
None


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 15 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
6.3
SUBJECT SETS ANALYSED
Section 7.3 of the CTP:

Treated set (TS): The treated set includes all subjects who were entered and treated with 
at least one dose of study drugs. The treated set will be used for safety analyses.

Pharmacokinetic parameter analysis set (PKS): This set includes all subjects in the 
treated set (TS) who provide at least one PK endpoint that was defined as primary or 
secondary and was not excluded due to a protocol deviation relevant to the evaluation of 
PK or due to PK non-evaluability (as specified in the CTP subsection 
‘Pharmacokinetics’). Thus, a subject will be included in the PKS, even if he contributes 
only one PK parameter value for one period to the statistical assessment. Descriptive 
and model based analyses of PK parameters will be based on the PKS.
[…]
Plasma concentration data and parameters of a subject will be included in the statistical 
pharmacokinetic (PK) analyses if they are not flagged for exclusion due to a protocol 
deviation relevant to the evaluation of PK (to be decided no later than in the Report Planning 
Meeting) or due to PK non-evaluability (as revealed during data analysis, based on the 
criteria specified below). Exclusion of a subject’s data will be documented in the CTR.
Relevant protocol deviations may be

Incorrect trial medication taken, i.e. the subject received at least one dose of trial 
medication the subject was not assigned to

Incorrect dose of trial medication taken

Use of restricted medications
Plasma concentrations and/or parameters of a subject will be considered as non-evaluable, if 
for example

The subject experienced emesis that occurred at or before two times median tmax of the 
respective treatment (Median tmax is to be determined excluding the subjects 
experiencing emesis),

A pre-dose concentration of BI 1323495 is >5% Cmax value of that subject in the 
respective treatment period

Missing samples/concentration data at important phases of PK disposition curve
The descriptive analysis of PK concentrations will be based on the ADS ADPC as described 
at the beginning of Section 7.


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 16 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Table 6.3: 1
Subject sets analysed
Subject set
Class of endpoint
TS
PKS
Analyses of PK endpoints 
X
Safety parameters
X
Demographic/baseline parameters
X
Important protocol deviations
X
Disposition
X
6.5
POOLING OF CENTRES
This section is not applicable, because the study was performed in only one centre.
6.6
HANDLING OF MISSING DATA AND OUTLIERS
Handling of missing data and outliers will be performed as described in the CTP, Section 7.5.
The only exceptions where imputation might be necessary for safety evaluation are AE dates. 
Missing or incomplete AE dates are imputed according to BI standards (see 001-MCG-
156_RD-01 (4)).
Missing data and outliers of PK data are handled according to BI standards (see 001-MCS-
36-472_RD-01) (5).
6.7
BASELINE, TIME WINDOWS AND CALCULATED VISITS
The baseline value is defined as the last measurement before administration of BI 1323495 in 
each period.
Section 6.1 of the CTP: Exact times of measurements outside the permitted time windows 
will be documented. The acceptable time windows for screening, the end of trial examination, 
and measurements and assessments scheduled to occur ‘before’ trial medication 
administrations are provided in the CTP Flow Chart.
If not stated otherwise in the Flow Chart, the acceptable deviation from the scheduled time
for the assessment of safety (e.g. vital signs, ECG, laboratory tests) will be ± 30 min.


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 17 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Adherence to time windows will be checked via the consistency check listings at the RPM.
Unscheduled measurements of laboratory data and vital signs data will be assumed to be 
repeat measurements of the most recent scheduled measurement (e.g. for follow-up or 
confirmation of a particular value). Therefore, unscheduled measurements will be assigned to 
the planned time point of the previous scheduled measurement. 


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 18 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
7.
PLANNED ANALYSIS
Safety analysis (refer to Section 7.8) will be performed by 
 and 
will be presented in Sections 15.1 to 15.4 of the CTR and in Appendix 16.2 and 16.1.13.1.
Inferential statistical analyses of PK endpoints (refer to Section 7.4 and Section 7.5.2) will 
also be performed by 
and will be presented in Section 15.5 of 
the CTR and in Appendix 16.1.13.3.
Descriptive data analysis of PK endpoints and concentrations will be performed by the 
department Translational Medicine and Clinical Pharmacology (TMCP) at BI and will be
presented in Section 15.6 of the CTR.
The format of the listings and tables will follow the standards defined in the BI corporate 
guideline “Reporting of Clinical Trials and Project Summaries” [001-MCG-159] (6) with the 
exception of those generated for PK-calculations (7).
The individual values of all subjects will be listed, sorted by treatment sequence, subject 
number, visit and actual treatment (if appropriate). 
The listings will be included in Appendix 16.2 of the CTR.
For end-of-text tables, the set of summary statistics for non-PK parameters is: 
N 
number non-missing observations 
Mean
arithmetic mean
SD
standard deviation 
Min
minimum 
Median
median 
Max
maximum
For analyte concentrations, the following descriptive statistics will additionally be calculated:
CV 
arithmetic coefficient of variation
gMean
geometric mean
gCV
geometric coefficient of variation
For PK parameters, the following descriptive statistics will additionally be calculated:
CV 
arithmetic coefficient of variation
gMean
geometric mean
gCV
geometric coefficient of variation
P10 
10th percentile
Q1 
1st quartile
Q3 
3rd quartile
P90 
90th percentile


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 19 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
The data format for descriptive statistics of concentrations will be identical to the data format 
of the respective concentrations. The descriptive statistics of PK parameters will be 
calculated using the individual values with the number of decimal places as provided by the 
evaluation program. Then the individual values as well as the descriptive statistics will be 
reported with three significant digits in the CTR.
Tabulations of frequencies for categorical data will include all possible categories and will 
display the number of observations in a category, as well as the percentage (%) for each 
treatment sequence/group. Percentages will be rounded to one decimal place and will be 
based on all subjects in the respective subject set whether they have non-missing values or 
not. The category 'missing' will be displayed only if there are actually missing values.
Units of variables should be given in the titles or column/row descriptors in square brackets 
(e.g. [mg]).
Exclusion of PK parameters
The ADS ADPP (PK parameters) contains column variables indicating inclusion/exclusion 
(APEXC) of a PK parameter and an analysis flag comment (APEXCO). All analyses based 
on the PKS will include parameters if they are not flagged for exclusion, that is APEXCO is 
equal to “Included”.
Exclusion of PK concentrations
The ADS ADPC (PK concentrations per time-point or per time-interval) contains column 
variables ACEXC and ACEXCO indicating inclusion/exclusion (ACEXC) of a concentration 
and an analysis flag comment (ACEXCO). Exclusion of a concentration depends on the 
analysis flag comment ACEXCO. For example, if ACEXCO is set to ‘ALL CALC’, the value 
will be excluded for all types of analyses based on concentrations. If ACEXCO is set to 
‘DESC STATS’ the value will be excluded from descriptive evaluations per planned time 
point/time interval. If ACEXCO contains the addition ‘TIME VIOLATION’ or ‘TIME 
DEVIATION’ the value can be used for further analyses based on actual times. If ACEXCO
is set to ‘HALF LIFE’, the value will be excluded from half-life calculation (and, as a 
consequence, any calculation that relies on λz) only; the value is included for all other 
analyses. Concentrations excluded from analysis will be listed in the CTR associated with an 
appropriate flag.
Further details are given in 001-MCS-36-472_RD-01 “Noncompartmental Pharmacokinetic / 
Pharmacodynamic Analyses of Clinical Studies” (5) and 001-MCS-36-472_RD-03 
“Description of Analytical Transfer Files and PK/PD Data Files” (11).
7.1
DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS
Only descriptive statistics are planned for this section of the report, based on the TS. The data 
will be summarised in total.


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 20 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
7.2
CONCOMITANT DISEASES AND MEDICATION
Frequency tables are planned for this section of the report, based on the TS.
Concomitant diseases will be coded using the coding system of the Medical Dictionary for 
Drug Regulatory Activities (MedDRA). Medications will be coded using the World Health 
Organization Drug Dictionary (WHO-DD). The coding version number will be displayed as a 
footnote in the respective output.
The diagnoses and medications will be listed. Subjects without any concomitant diagnoses or 
concomitant therapies should be marked with a “No” in the respective column.
A medication will be considered concomitant, if it

is ongoing at the time of the first administration of the respective treatment

starts within the analysis phase of the respective treatment (see Section 6.1 for a 
definition of treatments and analysis phases)
The relevance of the concomitant therapies to the evaluation of PK will be decided no later 
than at the RPM. 
7.3
TREATMENT COMPLIANCE
Section 4.3 of the CTP: Compliance will be assured by administration of all trial medication 
in the study centre under supervision of the investigating physician or a designee. The  
measured plasma concentrations of trial medication will provide additional confirmation of 
compliance.
It is not intended to list the compliance separately. Any deviations from complete intake will 
be addressed in the RPM (cf. TSAP Section 6.2) and described in the CTR.
7.4
PRIMARY ENDPOINTS
Relative bioavailability of BI 1323495 in plasma (i.e. the effect of itraconazole on the PK of 
BI 1323495) is to be determined on the basis of the primary pharmacokinetic endpoints
AUC0-tz and Cmax (see Section 5.1). 
7.4.1
Primary analysis of the primary endpoints
Section 7.3.1 of the CTP: The statistical model used for the analysis of the primary 
endpoints will be an analysis of variance (ANOVA) model on the logarithmic scale. That is, 
the PK endpoints will be log-transformed (natural logarithm) prior to fitting the ANOVA 
model. This model will include effects accounting for the following sources of variation: 
subject and treatment. The effect ‘subject’ will be considered as random, whereas the effect
‘treatment’ will be considered as fixed. The model is described by the following equation:


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 21 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
ykm = µ + τk + sm + ekm, where
ykm = logarithm of response measured on subject m receiving treatment k,
µ = the overall mean,
sm = the effect associated with the mth subject, m = 1, 2, ..., n
τk = the kth treatment effect, k = 1, 2,
ekm = the random error associated with the mth subject who received treatment k.
where sm~ N(0,
) i.i.d., ekm ~ N(0, 
 ) i.i.d. and sm, ekm are independent random variables. 
The indices ‘B’ and ‘W’ correspond to ‘between’ and ‘within’ variability, respectively.
Point estimates for the ratios of the geometric means (test/reference) for the primary 
endpoints (see Section 5.1) and their two-sided 90% confidence intervals (CIs) will be 
provided.
For each endpoint, the difference between the expected means for log(T)-log(R) will be 
estimated by the difference in the corresponding adjusted means (Least Squares Means). 
Additionally their two-sided 90% confidence intervals will be calculated based on the 
residual error from the ANOVA and quantiles from the t-distribution. These quantities will 
then be back-transformed to the original scale to provide the point estimate and 90% CIs for 
each endpoint.
The implementation for this analysis will be accomplished by using the XPKISTAT macro, 
based on PKS, and option BWU (Bioavailability/Bioequivalence, within-subject design, 
uncontrolled w.r.t. time).


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 22 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
7.5
SECONDARY ENDPOINTS
7.5.1
Key secondary endpoints
This section is not applicable as no key secondary endpoint has been specified in the 
protocol.
7.5.2
Secondary endpoints
The secondary PK parameter AUC0-∞(AUCINF_pred) will be assessed using the same 
methods as described for the primary endpoints.
7.7
EXTENT OF EXPOSURE
Descriptive statistics are planned for this section of the report based on the TS. The date and 
time of drug administration will be listed for each subject.


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 23 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
7.8
SAFETY ANALYSIS
All safety analyses will be performed on the TS. 
The safety data for treated subjects who failed to complete the study (dropouts or 
withdrawals) will be reported as far as their data are available. All withdrawals will be 
documented and the reason for withdrawal recorded.
7.8.1
Adverse Events
AEs will be coded with the most recent version of MedDRA.
The analyses of AEs will be descriptive in nature and will be based on BI standards as 
presented in the corporate guideline: “Analysis and Presentation of Adverse Event Data from 
Clinical Trials” [001-MCG-156] (8).
The standard AE analyses will be based on the number of subjects with AEs (and not on the 
number of AEs). 
For analysis, multiple AE occurrence data on the case report form (CRF) will be collapsed 
into one AE provided that all of the following applies:

All AE attributes are identical (lower level term (LLT), intensity, action taken, 
therapy required, seriousness, reason for seriousness, relationship, outcome, AE of 
special interest (AESI))

The occurrences were time-overlapping or time-adjacent (time-adjacency of 
two occurrences is given if the second occurrence started within one hour after end of 
the first occurrence).
For further details on summarization of AE data, please refer to [001-MCG-156] (8).
The analysis of AEs will be based on the concept of treatment-emergent AEs. That means 
that all AEs will be assigned to the screening, treatment or follow-up phases as defined in 
Section 6.1. Therefore, all AEs which occur through the treatment phase and throughout the 
REP will be considered as on treatment.
Section 5.2.6.1.4 of the CTP: The following are considered as AESIs:

Hepatic injury
A hepatic injury is defined by the following alterations of hepatic laboratory 
parameters:


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 24 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
o
An elevation of AST (aspartate transaminase) and/or ALT (alanine 
transaminase) ≥3-fold ULN combined with an elevation of total bilirubin 
≥2-fold ULN measured in the same blood sample, or
o
Aminotransferase (ALT, and/or AST) elevations ≥10 fold ULN
These lab findings constitute a hepatic injury alert and the subjects showing these lab 
abnormalities need to be followed up according to the 'DILI checklist’ provided in the 
ISF. In case of clinical symptoms of hepatic injury (icterus, unexplained 
encephalopathy, unexplained coagulopathy, right upper quadrant abdominal pain, 
etc.) without lab results (ALT, AST, total bilirubin) available, the Investigator should 
make sure that these parameters are analysed, if necessary in an unscheduled blood 
test. Should the results meet the criteria of hepatic injury alert, the procedures 
described in the DILI checklist should be followed.
Section 7.3.4 of the CTP: Note that AEs occurring after the last per protocol contact but 
entered before final database lock will be reported to Pharmacovigilance only and will not be 
captured in the trial database.
For more detail see the TSAP ADS plan.
According to ICH E3 (9), AEs classified as ‘other significant’ need to be reported and will 
include those non-serious and non-significant adverse events with 
(i) ‘action taken = discontinuation’ or ‘action taken = reduced’, or
(ii) marked haematological and other lab abnormalities or lead to significant concomitant 
therapy as identified by the Clinical Monitor/Investigator at the Report Planning Meeting. 
An overall summary of AEs (including AESIs) will be presented.
The frequency of subjects with AEs will be summarised by treatment, primary system organ 
class (SOC) and preferred term (PT). Separate tables will be provided for subjects with other 
significant AEs according to ICH E3 (9), for subjects with serious AEs, for subjects with 
drug-related AEs, for subjects with drug related serious adverse events and for subjects with 
AESIs.
The SOCs and PTs will be sorted by frequency (within SOC). The MedDRA version number 
will be displayed as a footnote in the respective output.
In addition, frequencies of subjects with non-serious AEs that had an incidence of > 5% for at 
least one treatment will be summarised by treatment, primary SOC and PT.
For disclosure of adverse events on EudraCT, additional information not included in a 
standard AE analysis will be performed. The following three entries will be created:

Adverse Events per arm for disclosure on EudraCT

Non-serious Adverse Events for disclosure on EudraCT

Serious Adverse Events for disclosure on EudraCT


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 25 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
7.8.2
Laboratory data
The analyses of laboratory data will be descriptive in nature and will be based on 
BI standards [001-MCG-157] (10). 
Laboratory data will be analysed qualitatively via comparison of laboratory data to their 
reference ranges. Values outside the reference range as well as values defined as possibly
clinically significant will be flagged in the data listings.
Clinically relevant findings in laboratory data will be reported as baseline conditions (at 
screening) or as AEs (during the trial) if judged clinically relevant by the investigator, and 
will be analysed as such.
It is the investigator's responsibility to decide whether a lab value is clinically significantly 
abnormal or not (at the RPM at the latest). 
Descriptive statistics of laboratory data will be calculated by planned time point based on the 
worst value of the subject at that planned time point (or assigned to that planned time point).
7.8.3
Vital signs
Descriptive statistics over time including change from baseline will be performed for vital 
signs (blood pressure and pulse rate). In the listing the difference from baseline will also be 
displayed.
For vital signs, descriptive statistics will be calculated by planned time point based on the last 
value of the subject at that planned time point (or assigned to that planned time point).
Clinically relevant findings in vital signs will be reported as AEs.
7.8.4
ECG
ECG recordings will be checked by the investigator for pathological results. Clinically 
relevant abnormal findings for ECG will be listed under 'Relevant Medical History / Baseline 
Conditions' (when they occurred during screening) or will be reported as AEs (when they 
occurred during treatment), and will be analysed as such.
No separate ECG listing will be provided.
7.8.5
Others
Physical examination
Physical examination findings will be reported as relevant medical history/baseline condition
(i.e., a condition already existent before intake of study drug) or as AE and will be
summarised as such. 
No separate listing or analysis of physical examination findings will be prepared.


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 26 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
8.
REFERENCES
1.
CPMP/ICH/363/96: "Statistical Principles for Clinical Trials", ICH Guideline Topic E9, 
Note For Guidance on Statistical Principles for Clinical Trials, current version.
2.
001-MCS-40-413: "Identify and Manage Important Protocol Deviations (iPD) ", current 
version, IDEA for CON.
3.
BI-KMED-COPS-TMP-0001: "iPD log", current version; IDEA for GEN.
4.
001-MCG-156_RD-01: “Handling of Missing and Incomplete AE Dates”, current 
version; IDEA for CON.
5.
001-MCS-36-472_RD-01: “Noncompartmental Pharmacokinetic/Pharmacodynamic
Analyses of Clinical Studies”, current version; IDEA for CON.
6.
001-MCG-159: “Reporting of Clinical Trials and Project Summaries”, current version; 
IDEA for CON.
7.
001-MCS-36-472: "Standards and processes for analyses performed within Clinical 
Pharmacokinetics/Pharmacodynamics", current version; IDEA for CON.
8.
001-MCG-156: “Analysis and Presentation of Adverse Event Data from Clinical Trials”, 
current version; IDEA for CON.
9.
CPMP/ICH/137/95: “Structure and Content of Clinical Study Reports”, ICH Guideline 
Topic E3; Note For Guidance on Structure and Content of Clinical Study Reports, 
current version.
10. 001-MCG-157: “Handling, Display and Analysis of Laboratory Data”, current version; 
IDEA for CON.
11. 001-MCS-36-472_RD-03: “Description of Analytical Transfer Files and PK/PD Data 
Files”, current version; IDEA for CON.


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 27 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies


Boehringer Ingelheim
TSAP for BI Trial No: 1405-0009
Page 28 of 28
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
10.
HISTORY TABLE
Table 10: 1
History table
Version
Date
(DD-MMM-YY)
Author
Sections 
changed
Brief description of change
Final
21-OCT-2019
None
This is the final TSAP without any 
modification